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Patients with epidermodysplasia verruciformis (EV) and biallelic null mutations of TMC6 (encoding EVER1) or TMC8 (EVER2) 
are selectively prone to disseminated skin lesions due to keratinocyte-tropic human β-papillomaviruses (β-HPVs), which lack 
E5 and E8. We describe EV patients homozygous for null mutations of the CIB1 gene encoding calcium- and integrin-binding 
protein-1 (CIB1). CIB1 is strongly expressed in the skin and cultured keratinocytes of controls but not in those of patients. 
CIB1 forms a complex with EVER1 and EVER2, and CIB1 proteins are not expressed in EVER1- or EVER2-deficient cells. The 
known functions of EVER1 and EVER2 in human keratinocytes are not dependent on CIB1, and CIB1 deficiency does not impair 
keratinocyte adhesion or migration. In keratinocytes, the CIB1 protein interacts with the HPV E5 and E8 proteins encoded 
by α-HPV16 and γ-HPV4, respectively, suggesting that this protein acts as a restriction factor against HPVs. Collectively, 
these findings suggest that the disruption of CIB1–EVER1–EVER2-dependent keratinocyte-intrinsic immunity underlies the 
selective susceptibility to β-HPVs of EV patients.
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Introduction
Epidermodysplasia verruciformis (EV; OMIM ID 226400) is a 
rare Mendelian genodermatosis. EV patients are highly and se-
lectively susceptible to skin diseases due to cutaneous human 
papillomaviruses (HPVs) of the β genus (Orth, 2006, 2008; de 
Jong et al., 2018). They are otherwise healthy and normally re-
sistant to other microorganisms including other viruses and 
skin-tropic pathogens and even all other cutaneous and mucosal 
HPVs. Early in childhood, these patients present with persistent, 
disseminated, flat warts and pityriasis versicolor–like lesions 
of the skin that are induced by β-HPVs. Some patients develop 
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nonmelanoma skin cancer, particularly on areas of the body ex-
posed to the sun. By contrast, β-HPV infection is widespread and 
asymptomatic in the general population. EV is transmitted as an 
autosomal recessive (AR) trait in most families but was shown 
to be X-linked recessive in one family (Androphy et al., 1985). 
Biallelic null mutations of either TMC6 or TMC8 encoding EVER1 
and EVER2, respectively, account for about half the patients and 
families displaying EV (Ramoz et al., 2002; Burger and Itin, 2014; 
Imahorn et al., 2017; de Jong et al., 2018). These genes are widely 
expressed throughout the body, including in leukocytes, but 
patients with null mutations display no consistent abnormali-
ties of the development or function of any subset of leukocytes 
(Lazarczyk et al., 2012; Crequer et al., 2013). EVER1 or EVER2 
deficiency in keratinocytes, which would normally express both 
proteins and are the natural and exclusive host cells of β-HPVs, 
has thus been proposed as the cellular basis of the disease (Orth, 
2006, 2008). The exceedingly narrow infectious phenotype and 
the lack of detectable leukocyte abnormalities prevented EV 
from being recognized as a primary immunodeficiency until 
the discovery of genetic etiologies in 2002 (Ramoz et al., 2002; 
Notarangelo et al., 2004; Casanova, 2015a,b). However, EV was 
shown to be an inborn error underlying viral lesions between 
1922 and 1946 by the works of Wilhelm Lutz and Edward Cock-
ayne (Lewandowsky and Lutz, 1922; Cockayne, 1933; Lutz, 1946), 
before the first descriptions of congenital neutropenia by Ralph 
Kostmann and inherited agammaglobulinemia by Ogden Bruton 
(Kostmann, 1950; Bruton, 1952).
Patients with an “atypical” form of inherited EV have recently 
been described (de Jong et al., 2018). These patients suffer from 
primary immunodeficiencies due to profound T cell defects 
caused by inactivating biallelic mutations of STK4 (Crequer et al., 
2012a), RHOH (Crequer et al., 2012b), CORO1A (Stray-Pedersen 
et al., 2014), TPP2 (Stepensky et al., 2015), DCL RE1C (Tahiat et al., 
2016), LCK (Li et al., 2016), RAS GRP1 (Platt et al., 2017), or DOCK8 
(Sanal et al., 2012; Liu et al., 2017). Other patients with atypical 
EV have T cell deficits of unknown genetic etiology (Azzimonti et 
al., 2005; Borgogna et al., 2014; Landini et al., 2014). In all these 
patients, persistent infection with β-HPVs causes skin lesions 
identical to those of patients with classic EV, but in a context of 
broader infectious manifestations, the breadth and severity of 
which depend on the mutated gene and the nature of the T cell 
deficit. Indeed, patients with inherited T cell deficiencies typ-
ically suffer from various viral, bacterial, fungal, and parasitic 
infections, including many infections of the skin and viral in-
fections in particular (Notarangelo et al., 2004; Fischer, 2015). 
These patients are also prone to various autoimmune and, more 
rarely, tumoral manifestations. An additional role of these gene 
products in keratinocytes has not been formally excluded, but 
the T cell deficit common to all these patients strongly suggests 
that full T cell development and function are required for pro-
tective immunity to β-HPVs. Intriguingly, not all T cell deficits 
seem to confer a predisposition to β-HPV–driven lesions, and 
not all patients with such deficits display lesions of this type. 
Finally, β-HPV–induced skin lesions resembling typical EV have 
also been reported in a third group of patients who are otherwise 
healthy years after successful allogeneic hematopoietic stem cell 
transplantation (HSCT) for severe combined immunodeficiency 
due to mutations of IL2RG and JAK3 (Laffort et al., 2004). As 
both these genes are also normally expressed in keratinocytes, 
this third type of EV might be caused by a persistent deficiency 
of their products in keratinocytes that is not corrected by alloge-
neic HSCT. The products of these genes may be physiologically 
connected with EVER1 and EVER2 in keratinocytes.
The molecular basis of “typical” EV remains elusive. One plau-
sible hypothesis is that β-HPVs are defective for a growth-pro-
moting function encoded by the E5 gene, located between the 
E2-L2 genes of cutaneous α-HPVs, or the E8 gene, located in the 
E6 region of γ-, κ-, and μ-papillomaviruses, and that EVER1/2 
deficiency may compensate for the missing viral function (Bravo 
and Alonso, 2004; Nonnenmacher et al., 2006; Orth, 2006, 
2008). Indeed, it has been shown in vivo that cottontail rabbit 
papilloma virus (CRPV)-E8 is essential for the development of 
lesions in rabbits (Hu et al., 2002; Nonnenmacher et al., 2006). 
EVER1 and EVER2 belong to a larger family of transmembrane 
channel–like (TMC) proteins (Keresztes et al., 2003; Kurima 
et al., 2003). TMC1 and TMC2 are components of the sensory 
transduction ion channel in inner ear hair cells (Kawashima et 
al., 2011; Pan et al., 2013; Kurima et al., 2015). Both TMC6 and 
TMC8 are broadly expressed in human tissues, but expression 
levels are generally lower for TMC8 (www .proteinatlas .org). No 
knockout mice have been reported for either of these genes. It has 
been suggested that EVER1 and EVER2 control intracellular zinc 
homeostasis in human leukocytes and keratinocytes through in-
teraction with the ER-resident zinc transporter ZnT1 (Lazarczyk 
et al., 2008, 2009, 2012). HPV16-E5α (E5α being encoded by mu-
cosal and E5β by cutaneous HPVs) has been shown to interact 
with EVER1/2 (Lazarczyk et al., 2008), and both HPV16-E5α and 
E8 from CRPV interact with ZnT1 (Nonnenmacher et al., 2006; 
Lazarczyk et al., 2008). It has also been suggested that EVER2 
modulates TNF receptor signaling in human keratinocytes (Gaud 
et al., 2013; Vuillier et al., 2014). The pathogenesis of EV-like le-
sions in patients with IL2RG and JAK3 mutations years after suc-
cessful HSCT also remains unknown. Overall, the pathogenesis 
of β-HPV–driven lesions in EVER1- and EVER2-deficient patients 
and the mechanisms by which human keratinocytes normally 
control β-HPVs remain unexplained. We investigated patients 
with typical EV but no mutations of TMC6 or TMC8. We hypoth-
esized that the discovery of novel genetic etiologies of EV might 
open up new avenues of investigation into the pathogenesis of EV 
and the interaction between human keratinocytes and β-HPVs.
Results
Clinical features of EV patients
We investigated 24 individuals with unexplained typical EV (P1–
P24) from six families originating from and living in five differ-
ent countries (Colombia, France, Iran, Switzerland, and Togo; 
Fig. 1 A). None of the patients carried mutations in the exons and 
flanking intron regions of TMC6 or TMC8. The cohort was clin-
ically homogeneous, with disseminated β-HPV–positive skin le-
sions at various sites on the body beginning in childhood or early 
adulthood (Table 1 and Fig. S1). β-HPV5 and/or -HPV8 genotypes 
have been identified in the lesions of all patients tested (12 of 24). 
Cutaneous squamous cell carcinoma (SCC) developed in 14 of the 
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24 patients, mostly on sun-exposed areas of the skin (Table 1). 12 
of the 24 patients died: two from disseminated skin cancer (at 
the ages of 71 yr for P13 and 21 yr for P16) and 10 from causes 
unrelated to EV (aged 47–91 yr). None of the patients displayed 
any other unusually severe infectious diseases despite exposure 
to a large number of different infectious agents in urban or rural 
areas of countries as diverse as Colombia, France, Iran, Switzer-
land, and Togo. The clinical features of all patients other than 
kindred F from Iran have been described in detail elsewhere with 
the confirmation of β-HPV genotype and/or typical histological 
signs of β-HPV infection (Lutz, 1946; Rueda and Rodriguez, 1976; 
Kienzler et al., 1979; Kremsdorf et al., 1984; Deau et al., 1991, 1993; 
Rueda, 1993; Saka et al., 2009; Arnold et al., 2011; Imahorn et al., 
2017). Case studies for all 24 patients are listed in Materials and 
methods. P13 and P14 were among the first EV patients to be 
documented by Wilhelm Lutz in 1946 (Lutz, 1946). Overall, these 
patients were clinically and virologically indistinguishable from 
patients with biallelic truncating mutations of TMC6 or TMC8, 
with an AR but unexplained inheritance of lesions due to β-HPVs.
Immunological features of EV patients
Immunophenotyping of the patients tested (P3, P5, P15, P16, and 
P17) revealed normal numbers and compartmentalization of cir-
culating T cells, B cells, and NK cells (Table S1) as in patients car-
rying homozygous inactivating mutations of TMC8 (Crequer et 
al., 2013). Furthermore, T cell function after CD3 stimulation (P3 
and P5; Table S2) and B cell function as measured by antibody re-
sponses to common DNA and RNA viruses (P1–P5; Table S3) were 
normal. This finding is also consistent with those for patients 
with EVER2 deficiency (Crequer et al., 2013) but not for patients 
with RHOH, MST1, CORO1A, ART EMIS, RAS GRP, DOCK8, and 
TPP2 deficiencies who suffer from CD4+ T cell lymphopenia and 
various degrees of impairment of circulating T cell response to 
CD3 stimulation (Crequer et al., 2012a,b; Sanal et al., 2012; Stray-
Pedersen et al., 2014; Stepensky et al., 2015; Tahiat et al., 2016; 
Liu et al., 2017; Platt et al., 2017). Finally, more detailed analyses 
of skin-homing T cell populations (CLA+, CCR10+, CLA+CCR4+, 
and CLA+CCR10+ subsets) revealed no frequency abnormalities 
in the five patients tested (P1–P4 and P15; Table S4), again con-
trasting with the smaller sizes of these subsets within the CD4+ 
compartment in RHOH-deficient patients (Table S4; Crequer et 
al., 2012b). These skin-homing subsets even displayed mild ex-
pansion in three EVER2-deficient patients (Crequer et al., 2013). 
Thus, none of the patients tested displayed any detectable lym-
phocyte abnormalities, suggesting that they suffer from a new AR 
genetic etiology of EV affecting keratinocyte-intrinsic immunity 
as in EVER1- and EVER2-deficient patients.
Identification of a 2.4-Mb chromosomal region by genome-
wide linkage (GWL)
We used GWL analyses to search for genetic etiologies of EV in 
this cohort. Kindreds A, D, E, and F were known to be consan-
guineous, and consanguinity was suspected for kindreds B and 
C. We confirmed that all patients were born to consanguineous 
parents (Table S5) by showing that their inbreeding coefficients, 
as estimated with FSuite (Gazal et al., 2014) and genotyping 
data obtained with the Affymetrix Genome-wide Human Sin-
gle Nucleotide Polymorphism (SNP) or Illumina Infinum Global 
Figure 1. Identification of homozygous 
mutations affecting human CIB1 in a cohort 
of 24 EV patients. (A) Pedigrees of six kindreds 
affected by EV. Familial segregation of homo-
zygous CIB1 mutations (m/m) in six consan-
guineous families indicating an AR pattern of 
inheritance with complete clinical penetrance. 
(B) Graphical representation of the CIB1 cDNA 
exon (c.CIB1) and protein (p.CIB1) structure 
with presentation of the EF-hand domains. The 
arrows at the top indicate the location of the 
cDNA positions affected by the CIB1 mutations 
found in the families, whereas those at the 
bottom indicate their consequences at protein 
level. *, stop codon; del, deletion; ins, insertion; 
fs, frameshift.
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Screening array, were high. GWL analysis was performed by ho-
mozygosity mapping on 22 members of two branches (termed A1 
and A2; Fig. 1 A) of the extended kindred A, P12 from kindred B, 
P14 from kindred C, P15 from kindred D, six members of kindred 
E, and four members of kindred F in two generations. A highly 
significant linkage peak was found on chromosome 15, with a log-
arithm of odds (LOD) score of 16.7 for a 2.4-Mb interval (Fig. S2, 
A and B), strongly suggesting genetic homogeneity across these 
kindreds. We then searched for allelic homogeneity by looking at 
the haplotypes common to the various families. Kindred A is an 
extended family with two branches: A1 and A2 (Fig. 1 A). These 
two branches originate from the same region of Colombia and 
are homozygous for the same 3.5-Mb haplotype encompassing 
the linked interval, consistent with a common ancestral muta-
Table 1. Comparison of the clinical phenotypes of the 24 EV patients described in this study
Patient Case Sex Age (yr) Age onset (yr)/SCC HPV type Skin lesions (location) SCC Reference
P1 A1.viii.4 F 50 12/no Unknown Head and hands No Rueda (1993)
P2 A1.viii.7 M 47* 6/18 8, 17, 20 Head, neck, trunk, hands, legs, 
and feet
Forehead Rueda (1993), case 11
P3 A1.viii.10 F 46 7/13 8, 20 Head, trunk, legs, arms, and 
hands
Forehead, lips Rueda (1993), case 12
P4 A1.viii.12 F 44 7/no 8 Head and trunk No Rueda (1993)
P5 A1.viii.15 M 37 5/17 8, 20 Head, trunk, hands, and upper 
legs
Forehead Rueda (1993), case 13
P6 A1.vi.13 M 47* 1/15 Unknown Head, trunk, hands, and legs Nose, trunk Rueda (1993), case 6
P7 A1.viii.30 M 47 5/10 5, 17, 36 Head, trunk, arms, hands, and 
legs
Canthus, nose Rueda (1993), case 7
P8 A2.ii.1 F 78* 1/47 5, 8, 20, 24 Head, trunk, and extremities Forehead Rueda (1993) and Rueda and 
Rodriguez (1976), case 1 both 
papers
P9 A2.ii.10 F Unknown 5/38 8, 9 Head, trunk, and extremities - Rueda (1993) and Rueda and 
Rodriguez (1976), case 2 both 
papers
P10 A2.ii.12 M 48* 1/26 Unknown Head, trunk, and extremities Forehead, lips Rueda (1993) and Rueda and 
Rodriguez (1976), case 3 both 
papers
P11 A2.ii.13 M 47* 3/27 5, 8, 20 Head, trunk, and extremities Forehead Rueda (1993) and Rueda and 
Rodriguez (1976), case 4 both 
papers
P12 B.ii.2 M 72* 23/43 8, 15 Head, trunk, arms, hands, and 
legs
Forehead, check, ear Kienzler et al. (1979)
P13 C.ii.1 F 71* Childhood/35 5 Head, neck, hands, and legs Scalp, nose Lutz (1946) and Arnold et al. 
(2011), case 1 both papers
P14 C.ii.2 F 91* <7/52 5 Head, neck, and hands Nose, hand, neck, 
forehead, scalp
Lutz (1946) and Arnold et al. 
(2011), case 2 both papers
P15 D.iv.2 F 59 Childhood/54 5 Head, neck, arms, hand, knee, 
and lower leg
Forehead, nose Imahorn et al. (2017)
P16 E.iv.4 F 21* 7/unknown Unknown Face and trunk Multiple (sun-
exposed skin)
Saka et al. (2009)
P17 E.iv.6 F Unknown* 5/unknown Unknown Face and trunk Unknown Saka et al. (2009)
P18 E.iv.8 F Unknown* Unknown/unknown Unknown Unknown Unknown Saka et al. (2009)
P19 E.iv.10 M 14 2/unknown Unknown Face and trunk Unknown Saka et al. (2009)
P20 F.v.2 M 47 3/46 Unknown Head, neck, trunk, and upper 
and lower limb
Forehead 
(basosquamous 
carcinoma)
This study
P21 F.v.3 M 44 2/no Unknown Head, neck, trunk, and upper 
and lower limb
- This study
P22 F.v.7 F 30 5/no Unknown Head, neck, trunk, and upper 
and lower limb
- This study
P23 F.vi.1 F 22 1/no Unknown Head, neck, trunk, and upper 
and lower limb
- This study
P24 F.vi.2 M 21 4/no Unknown Head, neck, trunk, and upper 
and lower limb
- This study
Information collected from listed references or oral communication with the treating physicians. Please see Fig. 1 A for individual deidentifiers. F, female; 
M, male; ages of death are marked with asterisks.
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tion. Kindreds C and D were not known to be related, but both 
are from Switzerland, albeit from different cantons. These two 
families share the same short homozygous 1.74-Mb haplotype en-
compassing the linked interval, suggesting a common ancestral 
mutation for these two Swiss families. The shared haplotype of 
kindreds C and D is part of the common haplotype of the Colom-
bian patients. These findings reduce the interval of interest on 
chromosome 15 to 1.74 Mb between positions 89.8 and 91.5 Mb. 
Overall, these results strongly suggest that the 24 patients from 
these six families have the same AR genetic etiology of EV, dif-
ferent from EVER1 and EVER2 deficiency, as the corresponding 
genes TCM6 and TCM8, which are organized in tandem, are ab-
sent from this interval.
Identification of bi-allelic mutations of CIB1
We then performed whole-exome sequencing (WES) on the 
probands from kindreds A–C and E (P7, P12, P14, and P19) and 
four patients from kindred F (P20–P23; Figs. 1 A and S2 C). This 
analysis identified CIB1 (encoding calcium- and integrin-binding 
protein 1; CIB1) as the only gene carrying a very rare homozy-
gous nonsynonymous coding mutation (minor allele frequency 
[MAF] < 0.001) in all patients tested. CIB1 is located within the 
1.74-Mb interval detected by GWL and homozygosity mapping, 
which contains 33 other protein-coding genes and nine RNA 
genes. In particular, no other gene within the interval of interest 
on chromosome 15 was homozygous for rare nonsynonymous 
coding variants common to all patients. The coding exons of the 
42 genes were all fully covered by WES. Sanger sequencing of 
genomic DNA confirmed that all 24 patients from the six kin-
dreds were homozygous for CIB1 mutations (m/m), whereas the 
34 unaffected family members tested were either heterozygous 
(wt/m) or homozygous for the WT (wt/wt) allele (Figs. 1 A and 
S2 D). The mutations were frameshift insertions (P1–P11, kin-
dred A: c.465_465+1insG; P12, kindred B: c.549_550insTT) and 
deletions (P13–15, kindred C and D: c.248_249delAA) predicted 
to cause premature stop codons (P1–P11: p.I156Dfs*5; P13–15: 
p.K83Rfs*4) or a stop loss (P12: p.A184Lfs*70), a nonsense allele 
(P16–P19, kindred E: c.214C>T, p.R72*), and an essential splice site 
mutation (P20–P24, kindred F: c.52-2A>G; Fig. 1 B) predicted by 
the Genscan algorithm (Burge and Karlin, 1997) to eliminate the 
acceptor site of exon 2 and to activate a cryptic acceptor site in 
intron 1. This would result in the retention of 319 bp of intron 1 
and the creation of a 47-aa protein product from exon 1 (aa 1–17) 
and part of intron 1 followed by a stop codon (aa 18–47). All 24 
patients from these six kindreds were homozygous for very rare 
mutations of CIB1 and had no other homozygous genetic lesion 
in common. Moreover, the segregation of the mutant alleles sug-
gested an AR trait with complete penetrance as in families with 
EVER1 or EVER2 deficiency.
The CIB1 mutations are predicted to be deleterious
The frameshift indels and splice-site mutations were not found 
in the public databases Genome Aggregation Database (gnomAD; 
Lek et al., 2016), Bravo (https:// bravo .sph .umich .edu/ freeze5/ 
hg38/ ), or the Greater Middle East variome project (http:// igm 
.ucsd .edu/ gme/ ; Scott et al., 2016), and they were also absent 
from our own in-house database of >4,500 exomes. The non-
sense R72* variant (dbSNP accession number rs143773090) was 
found in four heterozygous individuals from the total of 276,936 
individuals for whom data were available in the gnomAD, indi-
cating an allele frequency of <1.4 × 10−5, consistent with the very 
low prevalence of EV. Furthermore, no homozygous CIB1 non-
sense or frameshift mutations were present in these public or 
in-house databases. The gene-damage index (Itan et al., 2015) of 
CIB1 is very low (1.131). Mutations of CIB1 predicted to be delete-
rious, with a combined annotation-dependent depletion (CADD) 
score above the CIB1-specific mutation significance cutoff of 2.3 
(Kircher et al., 2014; Itan et al., 2016), are very uncommon in the 
general population, particularly in the homozygous state (only 
three missense mutations, each with a MAF <0.0027). The CADD 
scores of the CIB1 variants from the EV patients (35 for the inser-
tions, 27.7 for the deletion, 24.8 for the essential splice, and 40 for 
the nonsense variants) were well above the mutation significance 
cutoff. These genetic findings strongly suggest that these CIB1 
mutations, which are very rare or private to the six kindreds, are 
deleterious. Their strict unique recessive linkage with EV unam-
biguously demonstrates that homozygosity for deleterious CIB1 
alleles is a new AR genetic etiology of EV.
Lack of CIB1 expression in patients’ cells
The CIB1 protein is ubiquitous throughout the body and was first 
identified as an intracellular regulator of integrin signaling in 
platelets on the basis of its calcium-binding EF-hand domains 
(Fig. 1 B). Human CIB1 has since emerged as a regulator of diverse 
cellular processes including migration, adhesion, proliferation, 
and cell death/survival (Leisner et al., 2016; Wang et al., 2017). We 
first assessed the biochemical impact of the mutations by mea-
suring endogenous CIB1 mRNA and protein levels in leukocytes. 
Lymphoblastoid cell lines (LCLs) from P1–P5 and P7 had much 
lower levels of CIB1 mRNA than those from WT family members 
(wt/wt), whereas heterozygous (wt/m) family members had in-
termediate RNA levels (Fig. 2 A). The stop-loss mutation in P12 
is predicted to lead to an elongated transcript. The levels of CIB1 
mRNA in LCLs from P12 were higher than those for kindred A but 
much lower than those for WT controls (Fig. 2 A). P13 also had 
very low CIB1 mRNA levels in whole blood (Fig. 2 A), potentially 
reflecting nonsense-mediated mRNA decay due to the presence 
of premature stop codons. An antibody raised against an N-ter-
minal epitope of CIB1 located upstream from all the premature 
stop codons seen in the patients detected no endogenous CIB1 
protein in LCLs or peripheral blood mononuclear cells (PBMCs) 
from patients from kindreds A, B, and E, whereas CIB1 protein 
was detected in unrelated controls and healthy family mem-
bers (whether WT homozygous or heterozygous for the mutant 
alleles; Fig. 2 B). Thus, all the CIB1 mutations tested greatly de-
creased mRNA levels and resulted in a complete absence of CIB1 
protein from the cells tested. These data indicate that the patients 
had AR complete CIB1 deficiency.
CIB1 is expressed in keratinocytes
The ubiquitous pattern of expression and the pleiotropic func-
tions assigned to CIB1 are not easy to reconcile with the very 
narrow clinical phenotype of EV patients. β-HPVs have a strict 
tropism for the epidermis, and hair follicle stem cells probably 
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serve as a reservoir for HPV persistence (Orth, 2008). We there-
fore assessed CIB1 protein levels by immunohistochemistry 
(IHC) in skin biopsy specimens from healthy controls. A strong 
signal for CIB1 was obtained for the epidermis and hair follicles 
(Fig. 2 C). We then assessed CIB1 protein levels in cultured pri-
mary keratinocytes from three healthy controls, one hetero-
zygous healthy individual from kindred A (wt/m), and three 
patients from kindreds A, C, and D. CIB1 protein levels were high 
in control and heterozygous individuals, whereas this protein 
was not detected in the patients (Fig. 2 D). We also assessed CIB1 
protein levels in whole-skin biopsy lysates from a heterozygous 
individual of kindred F (wt/m) and in lysates from both lesional 
and nonlesional skin biopsy specimens from his relatives P21 
and P23. CIB1 protein was detected in the lysate from the het-
erozygous individual but not in lesional and nonlesional lysates 
from the patients (Fig. 2 D). Thus, CIB1 is clearly abundantly ex-
pressed in keratinocytes, the natural host cells of β-HPVs, and the 
patients’ skin and cultured keratinocytes display no detectable 
CIB1 expression. Finally, we showed that mRNA levels for CIB1, 
but also for TMC6 and TMC8, were not increased by type I IFN 
treatment in keratinocytes (Fig. S3), consistent with the lack of 
β-HPV lesions in patients with inborn errors of type I IFN immu-
nity (Dupuis et al., 2001, 2003; Ciancanelli et al., 2015; Kreins et 
al., 2015; Lamborn et al., 2017). Collectively, these findings sug-
gest that AR CIB1 deficiency may underlie EV by disrupting kera-
tinocyte-intrinsic type I IFN-independent immunity to β-HPVs.
Lack of CIB1 expression in EVER1- and EVER2-deficient cells
The clinical and virological phenotypes of EVER1-, EVER2-, and 
CIB1-deficient patients are indistinguishable. We therefore an-
alyzed CIB1 levels in LCLs derived from patients with EVER1 or 
EVER2 deficiency. Strikingly, individuals carrying inactivating 
mutations of either EVER1 (D576*; Ramoz et al., 2002) or EVER2 
(D362* [Ramoz et al., 2002] or T150Mfs*3 [Crequer et al., 2013]) 
had very low levels of CIB1 protein, whereas their heterozygous 
relatives had normal CIB1 protein levels (Fig. 3 A). In EVER1- and 
EVER2-deficient LCLs, CIB1 mRNA levels were ∼50% lower than 
in control LCLs (Fig. 3 B). EVER1 and EVER2 are therefore re-
quired for the correct expression of CIB1 protein. We detected 
normal EVER1 and EVER2 mRNA levels in CIB1-deficient LCLs 
(Fig. 3 B), but a lack of reliable antibodies against EVER proteins 
made it impossible for us to assess the levels of the correspond-
ing proteins. We also tested LCLs from patients with T cell de-
fects associated with persistent cutaneous β-HPV infections due 
to RHOH or MST1 (encoded by STK4) deficiency (Crequer et al., 
2012a,b). CIB1 levels were normal in cells from these patients 
(Fig.  3 A). This dichotomy mirrors the lymphocyte frequency 
data (Tables S1 and S4) and suggests that isolated β-HPV–induced 
disease in patients with typical EV is caused by a common EVER1/
EVER2- and CIB1-dependent mechanism different from the T 
cell–dependent mechanisms of disease in patients with atypical 
EV as well as infectious phenotypes including but not limited to 
β-HPV–induced lesions.
CIB1, EVER1, and EVER2 form a complex
These findings suggest that CIB1 protein stability might be con-
trolled posttranscriptionally by the EVER1 and EVER2 proteins. 
Consistent with this hypothesis, the stable overexpression of 
EVER1 in EVER1-deficient LCLs or of EVER2 in EVER2-defi-
cient LCLs rescued CIB1 protein (Fig. 3 C) but not mRNA levels 
(Fig. 3 D). As a control, the overproduction of either EVER protein 
in CIB1-deficient LCLs did not rescue CIB1 expression (Fig. 3, C 
and D). In the absence of robust antibodies against the EVER1 
and EVER2 proteins, overexpression was confirmed by assess-
ing mRNA levels (Fig. 3 D). These data suggest that EVER1 and 
EVER2 regulate CIB1 expression posttranslationally. We there-
fore hypothesized that the CIB1, EVER1, and EVER2 proteins 
form a multimeric complex that controls CIB1 protein stability. 
Reciprocal coimmunoprecipitation experiments in HEK293T 
cells showed that CIB1 interacted with both EVER1 and EVER2 
Figure 2. CIB1 levels in patient-derived cells and 
healthy skin biopsy specimens. (A) CIB1 mRNA levels 
were assessed by RT-qPCR in patient-derived LCLs for kin-
dred A and P12 and in whole blood from P13. Each symbol 
represents the mean of three independent measurements 
per cell line/donor. Statistical significance (***, P < 0.001) 
was assessed in a one-way ANO VA followed by Dunnett’s 
multiple comparison test for kindred A. Levels were 47% 
lower than the corresponding control mean in P12 and 80% 
lower in P13. (B) CIB1 protein was detected in LCLs and 
PBMCs with a polyclonal antibody directed against the N 
terminus of CIB1. GAP DH and Akt served as loading controls. 
Cellular material from kindreds A and B was analyzed three 
times. PBMCs from kindred E were analyzed once. (C) CIB1 
protein level in skin biopsy specimens from healthy donors 
were measured by IHC with a monoclonal antibody directed 
against CIB1. An isotype Ig was included as a control. These 
results are representative of two experiments, each per-
formed on two patients. *, epidermis; >, hair shaft. Bars: 
(top) 100 μm; (middle and bottom) 50 μm. (D) CIB1 protein 
was detected in primary keratinocytes from three healthy 
controls (ctrl 1–3), kindreds A, C, and D, or in whole-skin 
lysates from kindred F. L, lesion. These results are represen-
tative of three and one independent experiments, respec-
tively. Asterisk indicates a nonspecific band.
de Jong et al. 
CIB1 deficiency in epidermodysplasia verruciformis
Journal of Experimental Medicine
https://doi.org/10.1084/jem.20170308
2295
(Fig. 3 E). Subsequent immunofluorescence analysis in primary 
keratinocytes indicated that overproduced CIB1 was mostly lo-
calized in the nucleus. However, on coexpression with EVER1 or 
EVER2, CIB1 was localized in perinuclear and cytoplasmic web-
like structures that strongly colocalized with EVER1 or EVER2 as 
demonstrated quantitatively by the calculation of Pearson’s cor-
relation coefficient (Fig. 3 F). Furthermore, mass spectrometry 
on CIB1 immunopurified after its ectopic expression in HEK293T 
cells identified endogenous EVER1 as the highest-ranked interac-
tor of CIB1 (Fig. S4 A). EVER2 was not detected probably because 
its mRNA was barely detectable in HEK293T cells at levels lower 
than those of EVER1 by a factor of at least 60 (Fig. S4, B–D). Col-
Figure 3. CIB1 forms a complex with EVER1 and EVER2. (A) CIB1 protein levels in LCLs derived from patients with loss-of-function mutations of EVER1 
(D576*) and EVER2 (D362* or T150Mfs*3), and comparison with those in heterozygous carriers, positive controls (ctrl 1 and 2), P4 and P11, and patients with 
RHOH and MST1 deficiencies. (B) CIB1, EVER1, and EVER2 mRNA levels were assessed by RT-qPCR in controls (n = 4), CIB1 m/m (P1–P6 and P12), EVER1 m/m, 
and EVER2 m/m (n = 3 each) LCLs. Each symbol represents the mean of one cell line measured in three independent experiments. Statistical significance was 
assessed by one-way ANO VA followed by Dunnett’s multiple comparison tests relative to healthy controls. (C) CIB1 protein levels in LCLs derived from patients 
with loss-of-function mutations of EVER1 (D576*), EVER2 (T150Mfs*3), and a healthy control after reconstitution with WT EVER1 or EVER2 by retroviral trans-
duction and stable selection. Asterisk indicates a nonspecific band. (D) CIB1, EVER1, and EVER2 mRNA levels were measured by RT-qPCR in LCLs derived from 
patients with loss-of-function mutations of EVER1 (D576*), EVER2 (T150Mfs*3), or CIB1 and a healthy control after reconstitution with WT EVER1 or EVER2 by 
retroviral transduction and stable selection. The data were first normalized against RNaseP as a housekeeping gene and then against an appropriate untrans-
duced parental cell line by the ΔΔCt method. Statistical significance was assessed by one-way ANO VA followed by Dunnett’s multiple comparison test relative 
to the corresponding untransduced control. (B and D) ns, P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001. (E) HEK293T cells were transfected with plasmids 
encoding CIB1-HA, FLAG-EVER1, and FLAG-EVER2 either separately or together; 24 h after transfection, samples were subjected to immunoprecipitation with 
FLAG (Fl)- or HA-specific antibodies (+). Samples incubated with nonspecific IgG served as specificity controls. Western blots were performed to detect coim-
munoprecipitated CIB1-HA and FLAG-EVER1 or FLAG-EVER2. The immunoprecipitation of EVER1/2 and CIB1 was confirmed by reincubation with antibodies 
specific for FLAG and HA, respectively. The presence of all proteins was checked by Western blotting of an input sample taken before immunoprecipitation. 
GAP DH served as a loading control. vec, vector. (F) Healthy control keratinocytes were transfected with plasmids encoding CIB1-HA, FLAG-EVER1, and FLAG-
EVER2 either alone or in combination; 24 h after transfection, cells were subjected to immunofluorescence imaging with Alexa Fluor 568–HA and Alexa Fluor 
488–FLAG antibody combinations. DAPI was used for counterstaining. Colocalization was assessed by calculating Pearson’s correlation coefficient with Imaris 
software. Bar, 13 µm. The results shown are representative of three independent experiments.
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lectively, these data strongly suggest that a multimeric complex 
of CIB1 and EVER1/EVER2 proteins is required for CIB1 protein 
stability. They connect CIB1 directly with the previously identi-
fied EV-causing proteins EVER1 and EVER2.
CIB1 does not affect intracellular free zinc and NF-κB signaling
The interaction between CIB1 and EVER1/2 led us to investigate 
the contribution of CIB1 to the known functions of EVER1 and 
EVER2 (Lazarczyk et al., 2008; Vuillier et al., 2014). EVER1 and 
EVER2 have been reported to control intracellular zinc homeo-
stasis by binding to the zinc transporter ZnT1, increasing its ac-
tivity to import zinc into the ER storage compartment, thereby 
controlling free intracellular zinc levels (Lazarczyk et al., 2008). 
We overproduced EVER1 and EVER2 in HEK293T cells; both pro-
teins repressed the basal and zinc-induced transcription of a 
GFP reporter construct via the metal-response element (MRE; 
Günther et al., 2012; Fig. 4 A), consistent with previous findings 
(Lazarczyk et al., 2008). However, CIB1 overexpression had no 
effect on MRE activity, and no additional effect was observed 
when CIB1 was coexpressed with EVER1 or EVER2 (Fig. 4 A), 
consistent with the lack of colocalization of CIB1 and ZnT1 (Fig. 
S4 E). Moreover, our findings confirmed the interaction be-
tween the overproduced EVER1/2 and ZnT1 proteins (Lazarczyk 
et al., 2008), but we detected no interaction between CIB1 and 
ZnT1 in the same conditions (not depicted). At odds with this 
previous study (Lazarczyk et al., 2012), the absolute amounts 
of free zinc, determined with the fluorescent zinc reporter Flu-
ozin-3, were unaffected in LCLs from patients with EVER1 or 
EVER2 deficiency (Fig. 4 B). Consistent with these findings, P1–
P5, P7, and P12 also had normal free zinc levels in LCLs, and P14 
had normal amounts of zinc in primary keratinocytes (Fig. 4 B). 
Furthermore, all cell lines had zinc flux kinetics in the control 
range (Fig. 4 C). No statistically significant effect of genotype 
was detected in a two-way repeated-measures ANO VA. Thus, 
the overexpression of EVER1 and EVER2 modulated zinc-de-
pendent transcription, whereas that of CIB1 did not, and en-
dogenous EVER1/2 and CIB1 deficiencies had no overt effect on 
zinc homeostasis, implying that the mechanism underlying EV 
is zinc independent. Finally, an analysis of TNFα-dependent 
canonical and noncanonical NF-κB activation upon overexpres-
sion of EVER1, EVER2, CIB1, or a combination of these genes in 
HEK293T cells revealed no differences relative to an empty vec-
tor–transfected control (Fig. 4 D), at odds with previous studies 
(Gaud et al., 2013; Vuillier et al., 2014). Moreover, CIB1-deficient 
keratinocytes from P5 and P14 displayed normal NF-κB activa-
tion in response to TNFα, as shown by assessments of IκBα phos-
phorylation (Fig. 4 E). This finding is consistent with the fact 
that none of the many known inborn errors of NF-κB underlie 
skin lesions caused by β-HPVs (Zhang et al., 2017). Thus, studies 
of the known functions of EVER1 and EVER2 identified no phe-
notype common to EVER1-, EVER2-, and CIB1-deficient cells. As 
the three genetic deficiencies are AR with complete penetrance 
and underlie strict virological and clinical phenocopies and the 
three proteins are required for the stability of an oligomeric 
complex, these findings suggest that the major mechanism of 
EV pathogenesis is probably unrelated to zinc metabolism and 
NF-κB activation.
CIB1 deficiency does not affect keratinocyte 
adhesion and migration
We then focused our attention on the known functions of CIB1. 
None of the four phenotypes of CIB1-deficient mice were seen in 
our patients, who had no cardiac, vascular, hemostasis, or fertil-
ity abnormalities (Yuan et al., 2006; Zayed et al., 2007; Naik et al., 
2009; Heineke et al., 2010). CIB1 has not been studied in human 
or mouse keratinocytes. However, it has been reported to local-
ize to focal adhesions and to modulate cell migration (Leisner et 
al., 2016). The keratinocytes of P5 contained normal levels of the 
focal adhesion proteins vinculin and focal adhesion kinase (FAK) 
and displayed normal FAK activation, as shown by Western blot 
analyses of phosphorylation (pFAK), relative to two unrelated 
healthy controls and a heterozygous family member (Fig. 5 A). 
We assessed the formation of focal adhesions by performing im-
munofluorescence staining for vinculin- and pFAK-positive focal 
adhesion structures in CIB1-deficient keratinocytes. Automated 
surface detection and quantification showed these adhesions 
to be of normal size, fluorescence intensity, and morphology, 
similar to those of healthy controls and heterozygous relatives 
(Fig. 5, B and C). Consistent with these results, CIB1 deficiency 
had no detectable effect on the ability of keratinocytes to mi-
grate in scratch-wounding assays, although the results obtained 
were at the lower end of the control range (Fig. 5, D, E, and F). Fi-
nally, we compared the transcriptomes of WT keratinocytes and 
CIB1-deficient keratinocytes and of CIB1-deficient keratinocytes 
and GST- or WT-CIB1–transduced CIB1-deficient keratinocytes. 
We identified only 40 genes displaying at least a twofold down- 
or up-regulation. These genes included CIB1 but not EVER1 or 
EVER2, consistent with our quantitative PCR (qPCR) data. No 
enrichment in a specific pathway was detected among these 
genes (Table S6). Thus, the lack of CIB1 caused no overt cellu-
lar phenotype related or unrelated to the known functions of 
EVER1, EVER2, or CIB1 in LCLs or primary keratinocytes. These 
data are consistent with the very narrow clinical phenotype of 
EV patients, who are highly and selectively vulnerable to β-HPV 
but otherwise healthy. However, they provide no insight into the 
potential mechanism underlying β-HPV–driven lesions as even 
keratinocytes displayed no detectable phenotype.
CIB1, EVER1, and EVER2 interact with the HPV E5 
and E8 proteins
These results suggest that CIB1-deficient keratinocytes may dis-
play their EV-causing phenotype only in the presence of β-HPV 
infection. Antiviral restriction factors are commonly targeted 
and antagonized by viral proteins (Duggal and Emerman, 2012). 
The specific feature of the β-HPVs underlying EV lesions is their 
lack of the E5 and E8 open reading frames (ORFs), rendering 
them defective in healthy individuals (Orth, 2006). The E8 ORFs 
from μ-HPV1, γ-HPV4, and κ-CRPV are structurally related to the 
E5 ORF, and the corresponding proteins function as growth-pro-
moting factors in E5-deficient κ-papillomaviruses (Orth, 2008). 
Indeed, it has been shown that CRPV-E8 is crucial in vivo (Hu et 
al., 2002; Nonnenmacher et al., 2006). E5 and E8 are both hy-
drophobic transmembrane proteins with weak transforming 
activity in vitro (Nonnenmacher et al., 2006). As EV patients are 
prone only to cutaneous disease caused by β-HPVs, we hypoth-
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esized that the EVER1–EVER2–CIB1 complex interacts with E8 
and E5 produced early in infection. We considered γ-HPV4 E8 
and κ-CRPV E8, all β-HPV5 early-expressed ORFs (E1, E2, E6, and 
E7), and as controls, all α-HPV16 early-expressed ORFs (E1, E2, 
E5α, E6, and E7). We assessed the ability of the corresponding 
proteins to interact with CIB1 in the human keratinocyte cell line 
HaCaT in Duolink proximity-ligation assays (PLAs) by fluores-
cence microscopy followed by the automated surface detection 
and quantification of total fluorescence intensity. This approach 
can be used to detect proteins lying in close proximity and there-
fore likely to form a complex. This approach revealed that CIB1 
was indeed targeted by HPV4 E8, CRPV E8, and HPV16 E5 but 
also by HPV5 E1 and HPV16 E2 and not by any of the other six 
E proteins from these two HPVs (Fig. 6 A). We then confirmed 
these interactions by coimmunoprecipitation/immunoblotting 
in HaCaT cells (Fig. 6 B). Collectively, these experiments showed 
that CIB1 interacts with both the γ-HPV4 E8 and α-HPV16 E5 
proteins. These findings are consistent with a previous study 
showing that EVER proteins interact with HPV16 E5 (Lazarczyk 
et al., 2008). The interaction between β-HPV5 E1 and HPV16 E2 
and CIB1 but not between HPV5-E2 and CIB1 suggests that the 
CIB1–EVER1–EVER2 complex or at least CIB1 might be involved 
against other cutaneous or mucosal HPVs in patients without EV. 
All these observations provide a plausible mechanism of disease 
in patients with EV. β-HPVs lacking the E5 and E8 ORFs cannot 
overcome the CIB1–EVER1–EVER2 complex, which probably op-
erates as a restriction factor in keratinocytes (Fig. 7). Conversely, 
in patients lacking EVER1, EVER2, or CIB1, the lack of this restric-
tion factor allows β-HPV–driven lesions to develop.
Discussion
We report AR complete CIB1 deficiency as a new genetic cause 
of EV. We identified two frameshift insertions (I156Dfs*5 and 
A184Lfs*70), one frameshift deletion (K83Rfs*4 in two kindreds), 
one nonsense mutation (R72*), and one splice mutation (c.52-
Figure 4. Analysis of zinc signaling/levels and NF-kB activation in the presence and absence of CIB1. (A) HEK293T cells were transfected with plasmids 
encoding CIB1, EVER1, and EVER2 either alone or in combination and with a 4×MRE-dependent EGFP reporter construct. After 24 h, cells were stimulated 
overnight with PMA/ionomycin (10 ng/ml and 50 ng/ml, respectively) or zinc sulfate (ZnSO4; 100 µM). The next day, cells were stained with 1 µg/ml DAPI to 
exclude dead cells, and GFP fluorescence was determined with an LSR II flow cytometer. The RRR with the value for vector-transfected cells was set at 100%. 
Statistical significance was assessed by one-way ANO VA followed by Dunnett’s multiple comparison test relative to the appropriate vector-transfected control 
(ns, P > 0.05; *, P < 0.05; ***, P < 0.001; n = 3). (B) Flow cytometric quantification of absolute amounts of labile zinc in LCLs derived from healthy controls, 
EVER1-, EVER2-, or CIB1-deficient patients, or in keratinocytes from P14 with 1 µM FluoZin-3 as described by Haase et al. (2006). Statistical significance was 
assessed by one-way ANO VA followed by Dunnett’s multiple comparison test relative to the healthy controls (n = 3). (C) Kinetics of zinc flux in LCLs derived from 
healthy controls and EVER1-, EVER2-, or CIB1-deficient patients. Cells were loaded with 1 µM FluoZin-3 for 30 min. Fluorimetric measurement were performed 
on a Victor microplate reader. Baseline fluorescence was recorded every minute for 10 min. Cells were then loaded with 100 µM ZnSO4 and recorded for 15 
min. The specificity of the zinc signal was confirmed by adding the calcium-specific chelator BAP TA before the quenching of the signal with the zinc-specific 
chelator TPEN and recording for 20 min. No significant effect of genotype was detected in two-way repeat-measures ANO VA (n = 3). (D) HEK293T cells were 
transfected with plasmids encoding CIB1-FLAG, FLAG-EVER1, and EVER2 either alone or in combination. Cells were stimulated with 50 ng/ml TNFα 6 h after 
transfection, incubated overnight, and then harvested and processed for Western blotting. Membranes were probed for the canonical NF-κB component (p)
IκBa and the noncanonical NF-κB component p100/p52. Expression of the constructs used for transfection was verified by incubation with a FLAG-specific 
antibody. GAP DH served as a loading control (n = 3). (E) Primary keratinocytes from unrelated donors (controls 1 and 2), a healthy family member from kindred 
A1 carrying the mutation in a heterozygous state (A1.viii.2), and one patient each from kindreds A1 and C were stimulated with 10 ng/ml TNFα for 5, 10, or 20 
min and then harvested and processed for Western blotting. Membranes were probed for the canonical NF-κB component (p)IκBa. CIB1 levels were assessed 
with a polyclonal antibody. GAP DH served as a loading control. vec, empty vector (n = 3).
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2A>G) in 24 patients from six families from five ethnically and 
ecologically diverse countries: Colombia, France, Iran, Switzer-
land, and Togo. None of the heterozygous relatives of the patients 
show any clinical signs of EV, whereas all homozygous individ-
uals suffer from EV. The familial segregation of the mutant CIB1 
alleles is consistent with an AR trait displaying complete clinical 
penetrance, but CIB1 deficiency is associated with somewhat 
variable expressivity, as also reported for the deficiencies in fam-
ilies with EVER1 and EVER2 mutations (Orth, 2006, 2008; Burger 
and Itin, 2014). For example, in kindred A, the phenotype ranged 
from very mild manifestations in P1 and P4 to more aggressive 
disease with early cancer development in siblings P2, P3, and P5. 
Nevertheless, in all patients, CIB1 deficiency led to the develop-
ment of EV from the age of 23 yr onward (the age at which clini-
cal penetrance can be said to be complete in this cohort). Finally, 
none of these patients suffered from any other unusually severe 
infection, like patients with EVER1 or EVER2 deficiencies and 
unlike those with atypical EV and T cell deficits. AR CIB1, EVER1, 
and EVER2 deficiencies are therefore indistinguishable clinical 
and virological phenocopies, consistent with a typical form of EV.
CIB1 has been reported to have pleiotropic functions both in 
vitro in cell culture models and in vivo in knockout mice (Leisner 
et al., 2016). Mice lacking Cib1 have vascular, cardiac, and hemor-
rhagic phenotypes, and their males are sterile (Yuan et al., 2006; 
Naik et al., 2009). By contrast, none of these phenotypes were 
observed in patients, indicating that CIB1 is not essential for these 
functions in humans. Low CIB1 mRNA levels are unlikely to be 
causally associated with oligoasthenozoospermia-related steril-
ity (Sun et al., 2014) as a complete absence of the CIB1 protein 
had no effect on male fertility in our cohort. We know that this 
observation is robust because we have diagnosed 24 CIB1-defi-
cient patients from six kindreds originating from very diverse 
ethnicities. Our findings suggest that the only nonredundant 
function of CIB1 in humans in vivo is the control of β-HPVs in 
Figure 5. Focal adhesion formation and scratch 
wounding in CIB1-deficient keratinocytes. (A) Pri-
mary keratinocytes from two donors, a healthy member 
of kindred A (A1.viii.2; CIB1 wt/m), and P5 were allowed 
to adhere to fibronectin-coated plates (10 µg/ml) for the 
times indicated and were then harvested and processed 
for Western blotting. The membranes were probed for 
the focal adhesion (FA) components vinculin and (p)FAK. 
GAP DH served as a loading control. (B and C) Primary 
keratinocytes from two donors, a healthy member of 
kindred A (A1.viii.2), and P5 were allowed to adhere to 
fibronectin-coated coverslips (10 µg/ml) for 24 h. Cells 
were fixed and stained with vinculin- and pFAK-specific 
antibodies. Z stacks were acquired with a confocal micro-
scope. (B) Representative image for automated surface 
detection for control 1. Bar, 40 µm. (C) The volume (size), 
fluorescence intensity, and morphology of the vincu-
lin- and pFAK-positive structures were automatically 
determined with Imaris. Values were normalized against 
the total number of surfaces detected. Statistical sig-
nificance was assessed in one-way ANO VA followed by 
Dunnett’s multiple comparison test relative to control 1. 
No significant differences were detected for any of the 
parameters tested (P > 0.05). (D–F) Primary keratino-
cytes from two donors, a healthy member of kindred A 
(A1.viii.2; CIB1 wt/m), and P5 were allowed to adhere to 
fibronectin-coated plates (1 µg/ml) overnight. Scratch 
wounds were created with a pipette tip, and wound clo-
sure was monitored by live-cell microscopy every 20 min 
for 16 h. Bar, 283 µm. Wound closure was then quanti-
fied automatically with the MiToBo plugin in ImageJ with 
measurement of the cell-free area normalized against 
the starting point (set to 100%; D and E). Statistical sig-
nificance was assessed by two-way repeated-measures 
ANO VA. Differences between controls 1 and 2, CIB1 
wt/m, and P5 were statistically significant. Differences 
between control 2, CIB1 wt/m, and P5 were not signifi-
cant. (F) For confirmation of the accuracy of the results 
obtained with the plugin, the total cell-free area at the 
start and end points was determined manually. The data 
shown are the means of two (controls 1 and 2) or three 
(CIB1 wt/m and P5) independent experiments with at 
least six data points acquired per set. Statistical signif-
icance was assessed by one-way ANO VA followed by 
Dunnett’s multiple comparison test relative to controls 
1 or 2. (ns, P > 0.05; ***, P < 0.001).
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keratinocytes. Cib1-deficient mice have not been challenged with 
infectious agents including skin-tropic viruses. The only known 
mouse-tropic papillomavirus, Mus musculus papillomavirus 
type 1 (MuPV1; Ingle et al., 2011), does not belong to the β genus 
(Joh et al., 2011).
Our identification of AR CIB1 deficiency establishes a third 
genetic etiology of typical EV after AR EVER1 and EVER2 defi-
ciencies. Six different homozygous and two compound hetero-
zygous mutations of TCM6 have been described in 14 patients 
from eight kindreds (Ramoz et al., 2002; Tate et al., 2004; Zuo 
et al., 2006; Aochi et al., 2007; Gober et al., 2007; Youssefian et 
al., 2018), and 11 homozygous mutations of TCM8 have been de-
scribed in 17 patients from 11 kindreds (Ramoz et al., 2002; Sun 
et al., 2005; Berthelot et al., 2007; Rady et al., 2007; Landini et al., 
2012; Burger and Itin, 2014; Miyauchi et al., 2016; Imahorn et al., 
2017; de Jong et al., 2018; Youssefian et al., 2018). All these muta-
tions are loss of function. The identification of five homozygous 
loss-of-function alleles of CIB1 markedly increases the number 
of EV cases for which explanations have been found at the ge-
netic and molecular levels. Moreover, we identified a molecular 
connection between CIB1, EVER1, and EVER2 as shown by the 
very low levels of CIB1 proteins in cells from patients with EVER1 
or EVER2 deficiency. This is reminiscent of the interaction be-
tween TMC1, TMC2, and CIB2 in inner-ear hair cells, which is 
required for normal sensory transduction (Giese et al., 2017). Our 
observation provides a unifying cellular phenotype common to 
all known genetic etiologies of typical EV. CIB1 protein profiling 
could therefore be used as a simple laboratory test for screening 
patients with suspected EV, making it possible to target sequenc-
ing efforts on CIB1, TMC6, and TMC8 in patients with low levels 
of CIB1 protein.
The clinical characteristics of EVER1- and EVER2-deficient 
patients (EV in the absence of other clinical manifestations; 
Orth, 2006, 2008; Burger and Itin, 2014) and of the patients 
with CIB1 deficiency described in this study are identical and 
markedly different from those of patients with atypical EV due 
to CD4+ T cell lymphopenia caused by RHOH, MST1 (encoded by 
STK4), CORO1A, ART EMIS (encoded by DCL RE1C), DOCK8, RAS 
GRP1, LCK, and TPP2 deficiencies. In such patients, persistent 
β-HPV–induced lesions occur in the context of a much broader 
infectious, autoimmune, and tumoral phenotype (Crequer et al., 
Figure 6. PLA and coimmunoprecipitation in HaCaT. (A) HaCaT cells were transfected with plasmids encoding FLAG-HPV5 E1, E2, E6, and E7, FLAG-HPV16 
E1, E2, E5, E6, and E7, FLAG-HPV4 E8, FLAG–CRPV E8, and CIB1-HA alone or in combination. The day after transfection, samples were plated on microscopy 
slides, allowed to adhere, fixed in acetone, permeabilized, and subjected to Duolink PLAs with rabbit-HA– and mouse-FLAG–specific antibodies. Z stacks were 
acquired with a widefield microscope, and PLA-positive sites (defined as structures >0.35 µM2) were scored with Imaris software for 15–50 cells per condition. 
These pooled results were obtained in two independent experiments. The orange bars indicate the mean. (B) HaCaT cells were transfected with plasmids 
encoding CIB1-HA and the FLAG-tagged HPV E ORFs scoring positive in the PLA in A. 1 d after transfection, samples were subjected to immunoprecipitation 
(IP) with FLAG-specific antibodies. Western blots were performed to detect coimmunoprecipitated HPV5 E1, HPV16 E2, E5, HPV4 E8, and CRPV E8. The immu-
noprecipitation of CIB1 was confirmed by reincubation with a FLAG-specific antibody. The presence of all proteins was checked by Western blotting analysis 
on an input sample taken before immunoprecipitation. GAP DH served as a loading control (n = 3). vec, vector.
Figure 7. Mechanism underlying EV. (A) In the general population, the 
CIB1–EVER1–EVER2 complex restricts the transcription of minichromosome 
of β-HPV, leading to the absence of clinical manifestation. The proteins E5 and 
E8 expressed by the other cutaneous HPVs (α2-, α4-, γ-, and μ-HPVs) are able 
to antagonize the CIB1–EVER1–EVER2 complex. However, additional restric-
tion factors are probably contributing to the absence of HPV lesions in the vast 
majority of people. (B) In EV patients, the lack of CIB1–EVER1–EVER2 permits 
the transcription of β-HPV minichromosome, which leads to the develop-
ment of EV lesions on the skin. However, the probable presence of additional 
restriction factors against cutaneous HPVs other than β-HPVs accounts for 
their normal control, which does not differ from the general population.
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2012a,b; Sanal et al., 2012; Stray-Pedersen et al., 2014; Stepensky 
et al., 2015; Li et al., 2016; Tahiat et al., 2016; Liu et al., 2017; Platt 
et al., 2017). Consistent with this observation, the CIB1-deficient 
patients tested in this study had no detectable T-lymphocyte de-
fects in terms of either cell numbers or functions. The clinical 
and immunological dichotomy between typical and atypical EV 
is reflected at the cellular level by the profile of CIB1 expression 
profile, with very low levels of CIB1 in patients with EVER1 and 
EVER2 deficiencies but not in patients with RHOH and MST1 de-
ficiencies. These findings support the notion that patients with 
typical EV have intact adaptive immunity and suffer from an in-
born error of cell-intrinsic immunity, resulting in an inability to 
control β-HPV–driven keratinocyte proliferation.
Inherited CIB1 deficiency is not associated with any detect-
able, constitutive phenotype in keratinocytes in terms of the 
transcriptome, cell growth, migration, or adhesion. CIB1 defi-
ciency also has no impact on zinc homeostasis and NF-κB activa-
tion, suggesting that EVER proteins have other functions shared 
by CIB1 that are involved in the pathogenesis of EV. We reveal in 
this study a phenotype of CIB1, EVER1, and EVER2 deficiencies 
that is conditional on infection with β-HPVs. Our findings suggest 
that the CIB1–EVER1–EVER2 complex interacts in vivo with both 
cutaneous γ-HPV4 E8 and κ-CRPV E8 as well as with α-HPV16 
E5. In this light, it is plausible that β-HPVs that lack both the E5 
and E8 ORFs cannot overcome the CIB1–EVER1–EVER2 complex, 
unlike α-, γ-, and μ-HPVs and CRPV, which cause disease more 
widely in the general population (Fig. 7). Both E5 and E8 are hy-
drophobic and transmembrane proteins with weak transform-
ing activity in vitro but potent growth-promoting activity in vivo 
(Hu et al., 2002; García-Vallvé et al., 2005; Nonnenmacher et al., 
2006; Maufort et al., 2007; Orth, 2008; Wechsler et al., 2018). 
Conversely, the E5 and E8 proteins target and antagonize the 
CIB1–EVER1–EVER2 complex, thereby contributing to virulence 
to α-, γ-, and μ-HPVs, which cause cutaneous warts in the general 
population. By contrast, β-HPVs are capable of causing disease 
only in EV patients lacking the CIB1–EVER1–EVER2 complex. The 
interaction of β-HPV5 E1 and α-HPV16 E2 with CIB1 is probably 
not sufficient to antagonize the EVER–CIB1 complex, yet it sug-
gests that this complex might be involved in the pathogenesis of 
the disease caused by various HPVs. However, EV patients are 
apparently not more prone to develop common HPV warts, sug-
gesting that immunity against cutaneous non–β-HPVs relies on 
mechanisms other than the CIB1–EVER1–EVER2 complex (Fig. 7). 
We have established that EV is caused by mutations of the genes 
encoding the proteins of the CIB1–EVER1–EVER2 complex, which 
acts as a restriction factor for HPVs in keratinocytes through 
interaction with two viral E proteins, E8 and E5, which are ab-
sent from β-HPVs.
The CIB1–EVER1–EVER2 complex fulfills the five criteria com-
monly used to define restriction factors active against viruses 
(Duggal and Emerman, 2012). First, the lack of CIB1, EVER1, 
or EVER2 is clinically associated with EV, lesions of which are 
caused by β-HPVs. Second, patients lacking the CIB1–EVER1–
EVER2 complex display no other detectable cellular or clinical 
phenotype. Third, the CIB1–EVER1–EVER2 complex operates in 
keratinocytes, the host cells of β-HPVs. Fourth, E5 and E8 are 
viral virulence genes expressed by cutaneous α-, γ-, and μ-HPVs 
but not β-HPVs, and the products of these genes target the CIB1–
EVER1–EVER2 complex. Fifth, human CIB1 belongs to a multi-
gene family with four members. We do not provide experimental 
evidence for the control of β-HPVs by the CIB1–EVER1–EVER2 
complex in keratinocytes in vitro as this work would have gone 
well beyond the scope of this study given the technical difficul-
ties involved. Nevertheless, we provide the first in vivo evidence 
of a restriction factor operating in humans. Other restriction fac-
tors in humans have been validated in vitro or in animal models 
(Kluge et al., 2015; Subramanian et al., 2018). The pathogenesis 
of the β-HPV–driven skin lesions characteristic of EV in patients 
with AR CIB1, EVER1, or EVER2 deficiency involves the disrup-
tion of skin-restricted, cell-autonomous, nonhematopoietic, 
keratinocyte-intrinsic, IFN-independent restriction factor (the 
CIB1–EVER1–EVER2 complex)–mediated immunity against a 
specific set of defective viruses (β-HPVs, which lack E5 and E8).
Materials and methods
Patients and case studies
The clinical characteristics of all patients are summarized in 
Table 1. The experiments involving human subjects were con-
ducted in accordance with local, national, and international reg-
ulations and were approved by the French Ethics Committee, the 
French National Agency for the Safety of Medicines and Health 
Products, and the French Ministry of Research (protocol C10-13) 
as well as The Rockefeller University Institutional Review Board 
(protocol JCA-0700). Informed consent was obtained from all pa-
tients or their family members included in this study.
Kindred A (branches A1 and A2; P1–11)
Branches A1 and A2 of kindred A originate from the same region 
of Colombia, and affected individuals in these two branches of 
the family are homozygous for the same 3-Mb haplotype encom-
passing a disease-linked interval on chromosome 15 that harbors 
CIB1, consistent with a common ancestor for these two families.
Kindred A, branch A1 (Figs. 1 A and S1; Tables 1, S1 A, S2, S3, S4, 
and S5). P1–P5 were born to second-degree cousins (Fig. 1 A). The 
consanguinity of this family was confirmed by the high inbreed-
ing coefficient determined by SNP 6.0 array analysis (Table S5). 
Neither of the parents displayed any signs of cutaneous HPV infec-
tion or EV. The clinical characteristics of P2, P3, and P5 have been 
reported previously (Rueda, 1993). All five patients mounted nor-
mal antibody responses to various DNA viruses (HSV-1/2, varicella 
zoster virus, CMV, EBV, and hepatitis B) and RNA viruses (hepatitis 
A, hepatitis C, measles, rubella, and mumps) as shown by com-
parison with 12 healthy family members (Table S3). Furthermore, 
P1–P4 were extensively phenotyped for skin-homing total CD3+, 
CD4+, and CD8+ T cell subsets (CLA+, CLA+CCR4+, CLA+CCR10+, and 
CCR10+), and no alterations were detected relative to five unre-
lated healthy donors and nine healthy family members (Table S4).
P1 (A1.viii.4; Fig. 1 A) has a very mild EV phenotype. She first 
developed persistent flat warts on the back of her hands at the 
age of 12 yr. At the age of 15 yr, she developed warts on her face. 
She is not currently followed by a dermatologist.
P2 (A1.viii.7; Fig. 1 A) presented with brownish macules on his 
hands at the age of 6 yr. He was formally diagnosed at the age of 
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13 yr. The hyperpigmented lesions progressively spread, forming 
flat warts on his breast, neck, forehead, legs, and feet (Fig. S1 A). 
The lesions on his forehead were hypochromic, and the lesions 
on his trunk were pityriasis versicolor–like. He developed an 
invasive ulcerating SCC on the right-hand side of his forehead, 
which was surgically removed. He was treated by cryotherapy 
and with topical 5-fluorouracil. Restriction enzyme analysis and 
Southern blot hybridization showed that P2 was carrying HPV8, 
HPV17, and HPV20. P2 also suffered from chronic hepatitis C 
virus–induced hepatitis and died from hepatic carcinoma at the 
age of 47 yr. This patient was described as case 11 by Rueda (1993).
P3 (A1.viii.10; Fig. 1 A) presented with flat warts at the age of 7 
yr. She was formally diagnosed at the age of 13 yr. She displayed 
reddish and hyperpigmented flat warts on her forehead, trunk, 
arms, hands, and legs. She developed three SCCs on the fore-
head and lips after the age of 13 yr. Restriction enzyme analysis 
and Southern blot hybridization showed that P3 carried HPV8 
and HPV20. This patient was reported as case 12 in a previous 
study (Rueda, 1993). She displays no immunological abnormal-
ities of T cells, B cells, NK cells, or monocytes (Table S1 A), and 
her T cell proliferation after anti-CD3 antibody stimulation was 
normal (Table S2).
P4 (A1.viii.12; Fig. 1 A) presented with flat warts at the age of 7 
yr and was formally diagnosed at the age of 22 yr. Her lesions are 
located on the head and trunk. She has not yet developed SCCs. 
She was shown to be HPV8 positive by restriction enzyme analy-
sis and Southern blot hybridization.
P5 (A1.viii.15; Fig. 1 A) presented with flat warts on his fore-
head at the age of 5 yr. The lesions spread to his hands, trunk, and 
upper legs over time. He was formally diagnosed with EV at the 
age of 7 yr. He developed an SCC on his forehead at the age of 31 
yr, which was surgically removed. He is currently being treated 
by cryotherapy and protection against sun exposure. Restriction 
enzyme and Southern blot analyses showed that he carried HPV8 
and HPV20. This patient was described as case 13 in a previous 
study (Rueda, 1993). He displays no immunological abnormalities 
of T cells, B cells, NK cells, or monocytes (Table S1 A), and his T 
cell proliferation in response to anti-CD3 antibody stimulation 
was normal (Table S2).
P6 (A1.iv.13; Fig. 1 A) presented with diffuse flat warts at the 
age of 1 yr. He was formally diagnosed with EV at the age of 29 
yr. He had numerous lesions over his entire body except for the 
scalp, palms, soles of his feet, and mucous membranes. The backs 
of his hands and his arms and legs were particularly severely af-
fected. Erythematous squamous and pigmented lesions evolved 
to Bowen’s disease and recurrent invasive SCC after the age of 
15 yr. Histologically, these lesions consisted of large cells with 
an extensive clear cytoplasm and vacuolar nuclei in both the 
stratum spinosum and granular layer of the epidermis, a feature 
pathognomonic for EV. In semithin sections, inclusion bodies, 
also typical of EV, were identified. This patient died at the age of 
47 yr due to multiple aggressive SCCs. He was reported as case 
6 in a previous study (Rueda, 1993). Unfortunately, this patient 
died >35 yr ago, precluding genetic analysis.
P7 (A1.viii.30; Fig. 1 A), belonging to another branch of kin-
dred A1, displayed consanguinity because one of his parents was 
the offspring of second cousins. Familial consanguinity was con-
firmed by a high inbreeding coefficient determined by SNP 6.0 
array analysis (Table S5). From the age of 5 yr, P7 presented erup-
tions of pityriasis versicolor–like and scaly erythematous lesions 
on the face and neck, which spread as flat warts to his trunk, 
forearms, legs, and the backs of his hands. He developed infil-
trative lesions, histologically defined as Bowen’s disease, at the 
left medial canthus and on the nose. P7 was treated surgically for 
Bowen’s disease and then topically with retinoic acid and 5-flu-
oruracil. P7 tested positive for HPV5, HPV17, and HPV36 by re-
striction enzyme analysis and Southern blot hybridization. This 
patient was described as case 7 in a previous study (Rueda, 1993).
Kindred A, branch A2 (Fig. 1 A and Tables 1 and S5). P8–P11 were 
born to healthy parents. Familial consanguinity was suspected 
and confirmed on the basis of a high inbreeding coefficient in 
P11 as determined by 250K array analysis (Table S5). The clinical 
characteristics of P8–P11 have been described previously (Rueda 
and Rodriguez, 1976; Rueda, 1993). All patients had normal karyo-
types and serum Ig levels.
P8 (A2.ii.1; Fig. 1 A) first presented with EV at the age of 1 yr, 
but she was not formally diagnosed until the age of 59 yr. She 
presented with flat warts on her head, trunk, and extremities. 
She developed SCC on her forehead at the age of 47 yr. Restriction 
enzyme analysis and Southern blot hybridization demonstrated 
the presence of HPV5, HPV8, HPV20, and HPV24 in this patient. 
She died at the age of 78 yr. This patient was described as case 
1 in previous studies (Rueda and Rodriguez, 1976; Rueda, 1993). 
HPV5 was cloned from benign and malignant lesions from P8 and 
characterized (Deau et al., 1993). HPV20 was originally cloned 
from a benign lesion from P8 (Kremsdorf et al., 1984).
P9 (A2.ii.10; Fig. 1 A) first presented with EV at the age of 5 
yr, but she was not formally diagnosed until the age of 40 yr. She 
presented with flat warts on her head, trunk, and extremities. 
SCC development has never been reported for this patient. Re-
striction enzyme analysis and Southern blot hybridization con-
firmed that this patient was carrying HPV8. This patient was 
described as case 2 in previous studies (Rueda and Rodriguez, 
1976; Rueda, 1993). HPV5 from P9 was cloned and characterized 
as case B by Deau et al. (1991) and case 4 by Deau et al. (1993).
P10 (A2.ii.12; Fig. 1 A) first presented with EV at the age of 
1 yr. He was not formally diagnosed until the age of 40 yr. He 
presented with flat warts on his head, trunk, and extremities. He 
developed SCC on his forehead and lips after the age of 26 yr, and 
he died at the age of 48 yr. This patient was described as case 3 in 
two previous studies (Rueda and Rodriguez, 1976; Rueda, 1993).
P11 (A2.ii.13) first presented with EV at the age of 3 yr but was 
not formally diagnosed until the age of 36 yr. He presented with 
flat warts on his head, trunk, and extremities. He developed in-
vasive SCC and basal cell carcinoma on his forehead after the age 
of 27 yr. He died at the age of 48 yr. Restriction enzyme analysis 
and Southern blot hybridization confirmed that this patient was 
carrying HPV5, HPV8, and HPV20. He was described as case 4 in 
two previous studies (Rueda and Rodriguez, 1976; Rueda, 1993).
Kindred B (P12; Fig. 1 A and Tables 1 and S5)
P12 (B.ii.2; Fig.  1  A) was previously described in a case study 
(Kienzler et al., 1979). He was born to French parents in 1933. Po-
tential parental consanguinity was investigated by calculating an 
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inbreeding coefficient with FSuite software (Gazal et al., 2014). 
This analysis indicated that his parents were first cousins (Table 
S5). P12 presented with recurrent polymorphic skin lesions typ-
ical of EV from the age of 23 yr onwards. He developed several 
SCCs on the forehead, cheek, and ear ∼20 yr after the onset of 
the disease. The viral etiology of his disease was confirmed by 
the identification of HPV8 by restriction enzyme analysis and 
by Southern blotting. P12 had normal levels of Ig, complement 
components, and cellular immunity as shown by measurements 
of dinitrochlorobenzene sensitization, rosette assays, leukocyte 
migration, and lymphocyte proliferation. P12 died from natural 
causes at the age of 72 yr.
Kindred C (P13 and P14; Fig. 1 A and Tables 1 and S5)
P13 (C.ii.1; Fig. 1 A) and P14 (C.ii.2; Fig. 1 A) were among the first 
EV patients documented by Lutz, who was the first to describe 
this disease and followed these two sisters from 1929/1930 on-
wards (Lutz, 1946). Both patients were also described in a more 
recent study (Arnold et al., 2011). They were born to Swiss par-
ents who were shown to be consanguineous by inbreeding coeffi-
cient analyses (Table S5). P13 was born in 1912. She developed flat 
wart-like lesions on her neck, face, and on the backs of her hands 
in childhood, and these warts persisted throughout her life. After 
the age of 35 yr, she developed several actinic keratoses and SCC. 
She died of locally invasive SCC with regional lymph node me-
tastasis at the age of 71 yr. P14 was born in 1923 and developed 
symptoms of EV in early childhood. Persistent lesions spread 
from the neck and hands to the patient’s legs. After the age of 52 
yr, P14 developed several actinic keratoses, SCCs, and basal cell 
carcinomas that were clinically well managed by a combination 
of surgery and topical treatment. P14 died from natural causes at 
the age of 91 yr. HPV5 was identified by PCR amplification from 
specimens obtained from these two patients.
Kindred D (P15; Figs. 1 A and S1; Tables 1, S1 B, S4, and S5)
P15 (D.iv.2; Fig. 1 A) was born to consanguineous parents from 
Switzerland, and her phenotype was recently described in a 
case study (Imahorn et al., 2017). Familial consanguinity was 
confirmed by a high inbreeding coefficient determined with an 
SNP 6.0 array (Table S5). P15 developed first lesions during early 
childhood (Fig. S1 B). She was treated for several carcinomas in 
situ (Bowen type) and SCCs from the age of 54 yr onwards. HPV5 
was detected by PCR amplification and Sanger sequencing. This 
patient has no immunological abnormalities of T cells, B cells, or 
NK cells (Table S1 B). She was also extensively phenotyped for 
skin-homing total CD3+, CD4+, and CD8+ cells and T cell subsets 
(CLA+, CLA+CCR4+, CLA+CCR10+, and CCR10+), none of which dis-
played any marked difference relative to five unrelated healthy 
donors (Table S4).
Kindred E (P16–P19; Figs. 1 A and S1 C; Tables 1 and S5)
P16 (E.iv.4; Fig. 1 A), P17 (E.iv.6; Fig. 1 A), and P19 (E.iv.10; Fig. 1 A) 
were first described in a case study (Saka et al., 2009). In brief, 
P16–P19 were born to consanguineous parents from Togo. Fa-
milial consanguinity was confirmed on the basis of a high in-
breeding coefficient in an SNP 6.0 array analysis (Table S5). P16 
first developed papules on her face at the age of 7 yr, and these 
lesions subsequently disseminated over her entire body. She was 
diagnosed at the age of 15 yr and died at the age of 21 yr from a 
pulmonary metastasis secondary to the development of multiple 
SCCs on areas of the skin exposed to the sun. P17 first developed 
papules on her face at the age of 5 yr, and these lesions subse-
quently disseminated over her entire body. P18 was not included 
in the initial case study. Only limited information about her clin-
ical characteristics is available. She died in 2013 after an episode 
of fever. P19 is currently 14 yr of age and was first presented with 
disseminated skin lesions at the age of 2 yr (Fig. S1 C). P16, P17, 
and P19 had normal blood counts and renal and hepatic functions 
and were confirmed to be HIV negative. Histological analysis 
confirmed the presence of the pathognomonic cytopathic effect 
in a lesional skin biopsy. It was not possible to type the causal 
HPV due to infrastructure-related difficulties.
Kindred F (P20–P24; Figs. 1 A, S1 D, and S2; Tables 1 and S5)
Two patients, a 47-yr-old man and his 22-yr-old daughter, were 
referred to the Dermatology Department of the Tehran Univer-
sity of Medical Sciences for the evaluation of a chronic condition 
that had begun during childhood. Similar presentations were ob-
served in other family members, with five in total all born to con-
sanguineous parents, suggesting the presence of an AR Mendelian 
disorder in the extended family. All patients were healthy at birth, 
but they developed cutaneous lesions resembling widespread flat 
warts and thin plaques from the ages of 1–3 yr onwards. Multiple 
hyperpigmented plaques were observed on the skin of the male 
patient. These plaques had an occasionally verrucous surface and 
displayed ulceration and scaling with raised pearly borders. Three 
excisional biopsies of the ulcerated plaques revealed the pres-
ence of islands of infiltrative malignant cells in the dermis with 
palisading basaloid cells and polygonal squamous differentiation 
with areas of keratinization and intercellular bridges consistent 
with basosquamous carcinoma. The patient also had numerous 
slightly raised brown papules and plaques on the face, neck, arms, 
chest, and back of the hands, some coalescing into larger plaques 
with a papillomatous surface. Microscopic evaluations of these le-
sions revealed hyperkeratosis and acanthosis, with keratinocytes 
displaying coarse keratohyaline granules, perinuclear halos, and 
a blue-gray pallor characteristic of EV. A jaw x-ray (orthopanto-
gram) was performed to evaluate jaw keratocysts and other ab-
normalities suggestive of nevoid basal cell carcinoma syndrome, 
which were found to be within normal limits. The index case and 
one of his affected siblings were positive for HBsAg, and both re-
ported long-term hepatitis B infection and liver cirrhosis. The 
female patient had numerous erythematous or hyperpigmented 
papules with a flat surface, minimal scaling, and irregular borders 
on the face, neck, hands, and arms. Flat pink macules and larger 
patches with fine scales were present on the chest and upper 
arms. Biopsy of the lesions revealed pathological features typi-
cal of EV warts with minimal papillomatosis and hyperkeratosis, 
viral cytopathic effects, and a blue-gray hue.
Genome-wide linkage analysis and inbreeding 
coefficient determination
Genome-wide linkage analysis was performed essentially as 
previously described (Grant et al., 2011) but with minor modi-
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fications. 22 members of kindred A, P14, P15, and six members 
of kindred E were genotyped with the Affymetrix Genome-wide 
Human SNP array 6.0. P10 was genotyped with the Affymetrix 
Genome-wide Human Mapping 250K, and P11 was genotyped 
with the Affymetrix CytoscanHD array. Four members of fam-
ily F were genotyped with the Illumina Infinum Global Screen-
ing Array (642,824 SNP markers) using 200 ng genomic DNA 
in accordance with the manufacturer’s instructions (Illumina). 
Genotypes were called with the Power Tools Software Package 
(Affymetrix), and Chromosome Analysis Suite Software was 
used for P11. SNPs presenting more than one Mendelian incon-
sistency were discarded. SNPs were further filtered with pop-
ulation-based filters with PLI NK software (Purcell et al., 2007) 
according to the ethnicity of the kindred. A subset of markers 
common to the three arrays and optimized to decrease their 
linkage disequilibrium (LD) was used for parametric multipoint 
linkage analyses in MER LIN (Abecasis et al., 2002) for kindreds 
A1, A2, B, D, E, and F, considering founders to be second-degree 
relatives and assuming AR inheritance with complete penetrance 
and a deleterious allele frequency of 10−4. The family founders 
and unrelated individuals from HapMap CEU, MEX, and YRI 
were used to estimate allele frequencies for kindreds B and D, A1 
and A2, and E, respectively, and to define linkage clusters with an 
r2 threshold of 0.4. For kindred F, we estimated allele frequencies 
from an unrelated Iranian cohort of 82 healthy individuals.
We estimated the inbreeding coefficient F by Markov pro-
cesses to model homozygous states throughout the genome 
according to the FEstim method (Leutenegger et al., 2003). We 
used the FEstim_SUBS method to minimize LD between SNPs 
as recommended in a previous study (Gazal et al., 2014) for the 
random extraction of sparse markers at 0.5-cm intervals to cre-
ate 100 submaps. This strategy does not require the estimation 
of LD scores for the data, and F is estimated by calculating the 
median value of the estimates obtained from the different maps. 
FSuite v1.0.3 software was used to calculate FEstim and to infer 
the degree of parental consanguinity for each individual from the 
genome-wide human SNP array data (Gazal et al., 2014).
WES
The method used for WES has been described previously (Bolze 
et al., 2010; Byun et al., 2010). Briefly, genomic DNA extracted 
from the patients’ blood cells or LCLs was sheared with a Covaris 
S2 Ultrasonicator. An adapter-ligated library was prepared with 
the Paired-End Sample Prep kit V1 (Illumina). Exome capture was 
performed with the SureSelect Human All Exon kit (50- or 71-Mb 
version; Agilent Technologies). Sequencing was performed on an 
Illumina Genome Analyzer IIx (Illumina) generating 72- or 100-
base reads. For kindred F, DNA was extracted from peripheral 
blood samples by the salting out method. DNA concentration 
was measured with a Qubit 2.0 fluorimeter (Thermo Fisher Sci-
entific). WES was performed for probands and affected family 
members. Exons and flanking intronic regions of ∼20,000 genes 
(45 Mb; 98% of consensus coding sequence exons) were captured 
with the Illumina TruSeq Exome Enrichment Kit and sequenced 
on a NextSeq 500 instrument (Illumina). We used a BWA-MEM 
algorithm (Li and Durbin, 2009) to align the sequences with the 
reference human genome sequence (hg19build). Downstream 
processing was performed with the Genome Analysis Toolkit 
(GATK; McKenna et al., 2010), SAMtools (Li et al., 2009), and 
Picard Tools (http:// broadinstitute .github .io/ picard/ ). Substi-
tution calls were made with GATK UnifiedGenotyper, whereas 
indel calls were made with SomaticIndelDetector V2. All calls 
with a read coverage of <2× and a Phredscaled SNP quality of 
<20 were filtered out. Single-nucleotide variants were filtered 
on the basis of dbSNP135 (http:// www .ncbi .nlm .nih .gov/ SNP/ ) 
and 1000Genomes (http:// www .internationalgenome .org) data. 
All variants were annotated with ANN OVAR (Wang et al., 2010). 
The sequence data are available from the Sequence Read Archive 
website under accession number SRP151153. All variant calls with 
a variant quality <200, depth of coverage <5, and mapping qual-
ity <40 were filtered out. Only exonic and splice variants were 
retained, and synonymous and heterozygous variants were sub-
sequently removed. Single-nucleotide variants with a MAF of 
>0.1% in public databases were then excluded, given the rarity 
of EV. This process identified 26–56 variants per patient.
Sanger sequencing of genomic DNA
Genomic DNA samples from patients and their relatives were 
used as a template for the amplification of 300–600-bp regions 
encompassing the mutation by PCR with site-specific oligonu-
cleotides. Amplicons were sequenced with BigDye Terminator 
technology on an ABI 3730 DNA sequencer. Lasergene Suite 
and SnapGene were used for sequence analysis (DNA STAR 
and SnapGene). 
IHC
Briefly, skin punch biopsy specimens (6 mm in diameter) were 
obtained from waste skin removed from individuals undergoing 
abdominoplasty (two individuals). Biopsy specimens were frozen 
in optimal cutting temperature compound (Sakura) and stored at 
−80°C. Tissue sections were air dried, fixed with acetone, blocked 
by incubation with 10% normal serum, and stained with the an-
ti-CIB1 monoclonal antibody UN-2 (Naik et al., 1997) or an IgG1-κ 
isotype control (Sigma-Aldrich) at a concentration of 13 µg/ml 
overnight at 4°C. Tissue sections were thoroughly washed and 
incubated with biotin-labeled horse anti-mouse secondary anti-
body (Vector Laboratories) for 30 min at room temperature. The 
slides were then treated with 0.3% H2O2 and washed, and the 
staining signal was amplified with avidin–biotin complex Vec-
tastain (Vector Laboratories), activated with 0.015% H2O2, and 
developed with a 5% solution of the chromogen 3-amino-9-eth-
ylcarbazole (Sigma-Aldrich) for ∼20 min. IHC was performed on 
specimens from four healthy donors.
RNA sequencing
Total RNA was isolated from primary keratinocytes from P5 and 
P14, two healthy donors (control 1 and control 2), and cells from 
P5 stably expressing GST as an irrelevant protein or comple-
mented with an untagged CIB1 construct. Total cellular mRNA 
was prepared for sequencing with the NextSeq 500/550 High 
Output v2 kit. We generated 75-bp single reads on a NextSeq 
500. Reads were mapped onto the reference genome with STAR 
v2.5.3a (Dobin et al., 2013). A genome index specific to our data 
was first created, and the single-end reads were then aligned 
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in a two-pass strategy. In this strategy, new splicing junctions 
are first detected and used for the final mapping. Read counts 
were obtained for each gene with HTSeq v. 0.9.1 (Anders et al., 
2015). Gene expression levels were estimated with Transcripts 
Per Kilobase Million (TPM). TPM takes the size of each sample 
library and gene lengths into account to assess expression levels 
(Conesa et al., 2016). Statistical analysis was performed with R 
v.3.2.3 (The R Foundation, 2015). Gene expression profiles are 
represented as the log(fold change) in expression values between 
two different groups.
RT-qPCR
Human tissue
RNA was isolated from LCLs, primary keratinocytes, and 
HEK293T cells with the RNeasy mini kit and from whole blood 
with the PaxGene blood RNA kit (QIA GEN). Reverse transcription 
was performed with the SuperScript III first-strand synthesis 
system and oligo(dT) primers according to the manufacturer’s 
protocol (Thermo Fisher Scientific). RT-qPCR was then per-
formed with TaqMan assays using exon-spanning probes for CIB1 
(Hs01089679_m1), EVER1/TMC6 (Hs00273164_m1), or EVER2/
TMC8 (Hs00380060_m1; Thermo Fisher Scientific) with nor-
malization against GAP DH (4310884E), 18S (Hs99999901_s1), or 
RNaseP (4403326) as housekeeping genes by the ΔCT method. 
Data are represented as fold changes and were analyzed with the 
ΔΔCT method and comparison with an untreated control sample. 
The data shown are the means of three experiments.
Cell lines and primary cell isolation
HEK 293T cells were obtained from ATCC (CRL-3216). PBMCs 
were isolated by Ficoll-Hypaque density centrifugation (Amer-
sham Pharmacia Biotech) from cytopheresis or whole-blood 
samples obtained from healthy volunteers and patients, respec-
tively. EBV-immortalized LCLs (EBV-B cells) were obtained as 
previously described (Dupuis et al., 2001). Primary keratinocyte 
isolation: Punch biopsy specimens from the inner upper arm 
were washed three times with serum-free DMEM supplemented 
with 50 µg/ml gentamycin. They were then treated with dispase 
(354235; BD) at 4°C overnight. The following day, dermis and 
epidermis were separated manually and treated with Accutase 
(A6964; Sigma-Aldrich). The epidermis was then cut into pieces 
and wounded to obtain basal keratinocytes, which were cultured 
as described below.
Cell culture and transfection
HEK293T and HaCaT cells were maintained in DMEM supple-
mented with 10% FBS. LCLs were maintained in RPMI 1640 
supplemented with 10% FBS. Primary keratinocytes were main-
tained on mitomycin-C–inactivated (10 µg/ml; 3 h) MEF 3T3-J2 
feeder cells in complete Green medium (DMEM/Ham’s F12 in a 
2:1 ratio supplemented with 10% FBS, 180 nM adenine, 10 ng/ml 
EGF, 0.4 µg/ml hydrocortisone, 8.47 ng/ml cholera toxin, 5 µg/
ml insulin, 1.36 ng/ml triiodothyronine, and 10 µM ROCK inhib-
itor Y-27632). Transfections were performed with XtremeGENE 
9 (Roche), FuGENE6 (Promega), Lipofectamine 2000 (Thermo 
Fisher Scientific), or Lipofectamine LTX (Thermo Fisher Scien-
tific) in accordance with the manufacturer’s instructions.
Plasmids
Myc/DDK-tagged pCMV6-entry expression plasmids for EVER1/
TMC6, EVER2/TMC8, CIB1, HPV5 E1, E2, E6, and E7 as well as 
HPV16 E1, E2, E5, E6, and E7 were obtained from Origene. An 
HA-tagged CIB1 expression construct was generated by inserting 
the CIB1 expression cassette from pCMV6-entry into pcDNA3.1 
between the BamHI and EcoRI sites. CIB1 was amplified by PCR 
with the primers 5′-ATT AGG ATC CGC CAC CAT GGG GGG CTC GGG 
CAG TCGC-3′ and 5′-TCG AGA ATT CTC AAG CGT AAT CTG GAA CAT 
CGT ATG GGT ACA GGA CAA TCT TAA AGG AGC-3′. DDK-tagged 
pcDNA3.1+ expression constructs for CRPV E8 and HPV4 E8 were 
generated by inserting the E8 ORF (NCBI Reference Sequence 
NC_001541) amplified from the CRPV reference genome with 5′-
ATT AGG ATC CGC CAC CATGgactacaaggacgacgatgacaagGGA CCT 
GCA GAG ACT GC-3′ and 5′-tcgagaattcTTA ATC TTC TTC CGC AAA 
CTG-3′ primers between the BamHI and EcoRI sites and restric-
tion cloning the purified synthesized codon-optimized HPV4 
(gi|9626597) E8 ORF (from IDT) using the BamHI and EcoRI sites. 
Lowercase letters denote restriction sites.
We generated the pLZRS-IRES-ΔNGFR (de Paus et al., 2013; 
Martinez-Barricarte et al., 2016) expression plasmids for EVER1/
TMC6 and EVER2/TMC8 with the cold fusion cloning kit (System 
Bioscience) in accordance with the manufacturer’s instructions 
after linearization with EcoRI. The Myc/DDK-tagged expres-
sion cassettes were amplified by PCR from the abovementioned 
pCMV6 entry clones with the following primers: EVER1, 5′-ATT 
TAA ATT CGA ATT ATG GCC CAG CCA CTG GC-3′ and 5′-AGG CCT GCA 
GGA ATT TTA AAC CTT ATC GTC GTC ATC CTT GTA ATC CAG GAT ATC 
ATT-3′; and EVER2, 5′-ATT TAA ATT CGA ATT ATG CTG CTG CCG 
CGG-3′ and 5′-AGG CCT GCA GGA ATT TTA AAC CTT ATC GTC GTC 
ATC CTT GTA ATC CAG GAT ATC ATT-3′. The integrity of all expres-
sion cassettes was confirmed by Sanger sequencing.
Retrovirus production and transduction
Retroviruses containing EVER1- or EVER2-encoding or empty 
vectors were produced with the pLZRS-IRES-ΔNGFR constructs 
described above in Phoenix A cells as previously described 
(Martinez-Barricarte et al., 2016). Freshly harvested retrovi-
ruses were used to infect LCLs from a healthy WT control and 
EV patients with EVER1 D576* m/m, EVER2 T150M fs*3, or CIB1 
I156D fs*5. Cells were grown and purified as previously described 
(Martinez-Barricarte et al., 2016) but in RPMI 1640 supplemented 
with 10% FBS as the culture medium. Flow cytometry confirmed 
that the transduced and selected populations were >95% pure.
Immunoblotting and immunoprecipitation
Cells were lysed by incubation in radioimmunoprecipitation 
assay (RIPA) buffer supplemented with the inhibitors aprotinin, 
NaF, N-ethylmaleimide, Na3VO4, and leupeptin for 30 min on ice, 
and the resulting lysate was then cleared. For immunoprecipita-
tion, 10% of the lysate was set aside as the input control. Cleared 
lysates were incubated with 1 µg of the indicated antibodies 
(FLAG, HA, GFP, or an Ig control) at 4°C on an overhead tumbler 
for 2–16 h. Protein A–coupled magnetic Dynabeads (50 µl from a 
stock solution; Thermo Fisher Scientific) were added, and anti-
body-bound protein was captured from the lysate by incubation 
for 1 h at 4°C on an overhead rotator. Beads were washed three 
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to five times with 200 µl lysis buffer, resuspended in 100 µl lysis 
buffer, and transferred to new reaction tubes to prevent the coe-
lution of protein bound nonspecifically to the wall of the tube. 
The beads were resuspended in 25–50 µl 2× Laemmli buffer and 
boiled at 95°C for 5 min. Samples were subjected to standard SDS-
PAGE in Mini-Protean TGX 4–20% gels (Bio-Rad Laboratories), 
and the resulting bands were transferred onto polyvinylidene 
difluoride membrane by semidry transfer for 30–40 min at 200 
mA and 25 V per gel. The primary antibodies used were specific 
for CIB1 (raised against amino acids 24–43 [9, 11]), the HA epitope 
(HA.11-16B12; Covance), the FLAG epitope (M2; HRP coupled or 
unlabeled; Sigma-Aldrich), IkBa (L35A5), pIkBa (5A5), and p100/
p52 (18D10; Cell Signaling Technology), GAP DH HRP-coupled 
(FL-335), pFAK (2D11), and FAK (D-1; Santa Cruz Biotechnology, 
Inc.), vinculin (VIN-11-5; Sigma-Aldrich), GFP (JL-8; Takara Bio 
Inc.), and actin (137CT26.1.1; Abgent). We used normal rabbit and 
mouse IgG (Santa Cruz Biotechnology, Inc.) as immunoprecipi-
tation controls. The secondary antibodies used were HRP-cou-
pled anti-mouse IgG and anti-rabbit IgG (GE Healthcare) or 
anti-chicken IgY (Jackson ImmunoResearch Laboratories, Inc.). 
Antibody binding was detected by enhanced chemiluminescence 
with hyperfilm ECL or an RGB 600 Imager (GE Healthcare). The 
data shown are representative of at least three independent ex-
periments unless too little material was available. See the figure 
legends for details.
Immunofluorescence, PLA, and microscopy
Primary keratinocytes were plated on poly-L-lysine–coated cov-
erslips and transfected as indicated above. The cells were fixed by 
incubation with 4% PFA 24 h after transfection, permeabilized, 
and blocked by incubation in 0.2% Triton X-100, 3% BSA, and 
10% normal serum, and then they were incubated overnight with 
the primary antibody. The antibodies used were directed against 
the FLAG (anti-DDK; Origene) and HA epitopes (Sigma-Aldrich) 
and were used at a dilution of 1:500. The secondary antibodies 
used were Alexa Fluor 488– or 568–conjugated goat anti-mouse 
or anti-rabbit IgG (Thermo Fisher Scientific) at a dilution of 
1:500. Cells were counterstained with DAPI (0.5 µg/ml). Cover-
slips were mounted on slides in Prolong Antifade Gold (Thermo 
Fisher Scientific). Images were acquired with a DeltaVision 
Image Restoration microscope (Applied Precision Ltd.) using a 
60× oil-immersion objective and 0.24-µm steps. Images were 
deconvoluted with SoftWoRx software. Deconvoluted z stacks 
were subjected to automated image and colocalization analysis 
with Imaris software (Bitplane). Representative data from three 
independent experiments are shown. For focal adhesion analysis, 
primary keratinocytes were plated on fibronectin-coated (10 µg/
ml; Corning) coverslips, to which they were allowed to adhere for 
24 h. Cells were fixed with 4% PFA, permeabilized with 0.3% Tri-
ton X-100, blocked in 5% normal serum and 0.3% Triton X-100, 
and incubated overnight with the primary antibody. The anti-
bodies used were directed against vinculin (VIN-11-5; Sigma-Al-
drich) and pFAK (44-624G; Thermo Fisher Scientific), and they 
were used at a dilution of 1:500. The secondary antibodies used 
were Alexa Fluor 488–conjugated goat anti-mouse or anti-rabbit 
IgG at a dilution of 1:500–1,000 (Thermo Fisher Scientific). Cells 
were counterstained with Alexa Fluor 568–phalloidin (1 U phal-
lotoxin/slide; Thermo Fisher Scientific) and DAPI (0.5 µg/ml). 
Images were acquired with an AxioObserver.Z1 epifluorescence 
microscope (ZEI SS) equipped with an ORCA-ER camera (Hama-
matsu Photonics) and an ApoTome.2 (ZEI SS) with a 40× 1.4 NA oil 
immersion objective in 0.24-µm steps with Zen software (ZEI SS). 
Z stacks were subjected to automated image analysis and surface 
detection with Imaris software. Focal adhesions were defined as 
vinculin- or pFAK-stained surfaces with a volume >0.002 mm3 
within the lower half of the z stack. The parameters analyzed 
included volume, fluorescence intensity, and morphology (mea-
sured as ellipticity). Values were normalized relative to the total 
number of surfaces detected to obtain a mean per detected sur-
face structure. The data shown are the mean and SD of three ex-
periments with eight data points per set. For PLAs, HaCaT cells 
were transfected with CIB1-HA or the indicated myc-DDK–tagged 
HPV5 and HPV16 E ORF plasmids alone or in combination. Cells 
were transferred to poly-L-lysine–coated coverslips after 24 h. 
They were allowed to adhere for another 24  h and were then 
fixed in ice-cold acetone. Duolink PLA (Sigma-Aldrich) was per-
formed in accordance with the manufacturer’s instructions with 
anti-rabbit HA (Sigma-Aldrich) and anti-mouse DDK (Origene) 
antibodies at a dilution of 1:400 and then were incubated over-
night at 4°C with the cells. Duolink In Situ Detection Reagents Red 
was used for visualization.
Reporter gene assay
HEK293T cells were cotransfected with the indicated plasmids 
and pMRE-GFP, a GFP reporter construct driven by four copies 
of a MRE 5′-TGC ACTC-3′ (provided by W. Schaffner, University 
of Zurich, Zurich, Switzerland). This element is activated by the 
zinc-dependent metal transcription factor 1 (MTF-1). After 24 h, 
cells were stimulated with PMA/ionomycin (10 ng/ml and 50 ng/
ml; Sigma-Aldrich) or ZnSO4 (100 µM) overnight. The next day, 
cells were stained with 1 µg/ml DAPI to exclude dead cells, and 
fluorescence was acquired with an LSR II flow cytometer (BD). 
Results are shown as the relative response ratio (RRR) calculated 
as RRR= 100% × (sample − negative control)/(positive control − 
negative control). Untreated mock-transfected cells served as the 
negative control, and untreated vector-transfected cells served as 
the positive control. The data shown are the mean and SD of three 
independent experiments.
Determination of absolute free zinc levels and zinc kinetics
Labile zinc levels in LCLs and keratinocytes were determined 
by flow cytometry as previously described (Haase et al., 2006). 
Briefly, cells were loaded with the zinc-specific fluorescent 
probe FluoZin-3 (1 µM; Thermo Fisher Scientific) for 30 min at 
room temperature. Samples were either left untreated (F sam-
ple) or were treated with ZnSO4 and the zinc ionophore pyrithi-
one/2-mercaptopyridine N-oxide (referred to as Fmax; 100 µM 
and 50  µM; Sigma-Aldrich) or the zinc chelator TPEN (Fmin; 
100  µM; Sigma-Aldrich). All samples were stained with DAPI 
(0.5 µg/ml) to exclude dead cells. Fluorescence was recorded on 
an LSR II flow cytometer. The concentration of intracellular la-
bile zinc was calculated from the mean fluorescence according 
to the formula [Zn] = KD × ([F − Fmin]/[Fmax − F]). The dissoci-
ation constant of the FluoZin-3/zinc complex is 15 nM. The data 
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shown are the means of three independent experiments for LCLs 
and the mean and SD of three independent experiments for ke-
ratinocytes. For zinc kinetic measurements, LCLs were stained 
with FluoZin-3 (1  µM; 30 min at room temperature) in HBSS 
(Thermo Fisher Scientific) and then allowed to rest for 60 min 
at room temperature. Fluorescence was recorded on a VIC TOR 
plate reader (PerkinElmer). Baseline fluorescence was monitored 
every 60 s for 10 min. Cells were then sequentially loaded with 
ZnSO4 (100 µM), the calcium chelator BAP TA (25 µM; Sigma-Al-
drich), and the zinc-specific chelator TPEN (200 µM). In each set 
of conditions, fluorescence was determined every 60 s for 10–20 
min. BAP TA treatment ensured the specificity of the zinc signal. 
Unstained cells were used to correct values for background flu-
orescence. The data shown are the mean and SD for three inde-
pendent experiments.
Flow cytometry/immunophenotyping
Whole blood was either processed directly or used for the isola-
tion of PBMCs on a Ficoll density gradient. The PBMCs obtained 
were then either processed directly or frozen for future use. We 
lysed the red blood cells by incubating 100 µl fresh whole blood 
with fluorophore-conjugated antibodies for 20 min and then with 
FACS lysing solution (BD) for 10 min at room temperature. The 
antibodies used for staining were CD45-FITC, CD3-PE-Cy7, CD19-
PE-Cy7, CD4–Pacific Blue, CD14-V450, CD8-PE-Cy5, CD8-V450, 
or CD16-CD56-PE, CD45RA-FITC, CCR7-PE, and CD3-APC. Fluo-
rescence was measured on a FAC SCanto II flow cytometer (BD). 
Frozen PBMCs were thawed, washed, and incubated with Zombie 
UV viability dye (BioLegend) and then with fluorophore-conju-
gated antibodies in brilliant stain buffer (BD) for 30 min. The 
antibodies used were CD45RO-BV421, CD4-BV605, CCR4-BV421, 
CLA–Alexa Fluor 647, CD45RA–Alexa Fluor 488, CCR7–Alexa 
Fluor 647, CD8-PE-Cy7, HLA-DR-FITC, CD16-APC-Cy7, CD20-PE 
(BioLegend), CD3-PerCP-Cy5.5, CCR10-BB515, and CD56-APC 
(BD). Fluorescence was measured on an LSR II flow cytometer. 
Data were analyzed with FlowJo software (v.9.8.3; Tree Star). 
Whole-blood experiments were performed for two patients (P3 
and P5). Frozen PMBCs from healthy donors (n = 5), WT family 
members (n = 5), healthy heterozygous family members (n = 4), 
and patients (n = 5; P1–P4 and P15) were used. The data were ob-
tained in a single–time point experiment.
T cell proliferation assay
Freshly isolated PBMCs were loaded with carboxyfluorescein 
succinimidyl ester (5  µM; Invitrogen) for 5 min, washed, and 
plated at a density of 1 × 105 cells/ml in RPMI 1640/10% FBS 
supplemented with 2% penicillin/streptomycin on plates coated 
with anti-CD3 antibody (5, 2.5, or 1.25 µg/ml; clone UCHT1). Cells 
were then stimulated with anti-CD28 antibody (1 µg/ml; clone 
ANC28/5D10) for 3 d at 37°C in a humidified incubator under an 
atmosphere containing 5% CO2. Cells were harvested and pro-
cessed for flow cytometry by incubation with an APC-conjugated 
anti-CD3 antibody in flow cytometry buffer for 20 min. Fluo-
rescence was measured on a FAC SCanto II flow cytometer. The 
data were analyzed with FlowJo software using the proliferation 
analysis tool. The parameters displayed included proliferation 
index (the total number of divisions divided by the number of 
cells entering division), division index (the mean number of cell 
divisions undergone by a cell from the original population), and 
percent division (precursor frequency). The data shown were 
obtained in a single–time point experiment on specimens from 
two patients (P3 and P5) and two controls processed in parallel.
Scratch wound healing assays
Primary keratinocytes were plated on fibronectin-coated (10 
µg/ml; Corning) glass-bottomed six-well culture plates (Mat-
Tek). The cells were allowed to adhere to the plates overnight, 
and the resulting monolayer was then scratched with a pipette 
tip. Wound closure was monitored every 20 min for 16 h with an 
inverted Andor-driven spinning-disk confocal system equipped 
with a Zyla 4.2 (Andor Technology) camera in brightfield con-
ditions with a 10× 0.3 NA air objective. During imaging, cells 
were maintained at 37°C under an atmosphere containing 5% 
CO2. The images were subjected to automated analysis with the 
MiToBo plugin in ImageJ (National Institutes of Health) to de-
termine the cell-free area, which was normalized relative to the 
initial cell-free area and expressed as a percentage. The start and 
endpoint images were also manually analyzed by measuring the 
total cell-free area with the freehand tool. The data shown are the 
means for two to three experiments with at least six data points 
per experiment.
Large-scale protein purification and mass 
spectrometry analysis
For identification of the cellular partners interacting with CIB1, 
we transfected HEK239T cells (∼107 cells per 10-cm dish) in 10 
dishes with 12 µg plasmid encoding CIB1-FLAG or ORF75-FLAG 
(control) in the presence of GenJet transfection reagent (Sig-
naGen). 36 h later, the cells were lysed with RIPA buffer sup-
plemented with protease inhibitor cocktail and centrifuged 
at 13,000 rpm for 20 min at 4°C. Lysates were precleared with 
100 µl Sepharose 4B (Sigma-Aldrich) to remove cell debris and 
then were mixed with a ∼50% slurry of anti-FLAG M2 Affin-
ity Gel (Sigma-Aldrich) and incubated for 4 h at 4°C. The beads 
were thoroughly washed in lysis buffer, and the bound proteins 
were eluted by heating samples in 2× Laemmli SDS sample buf-
fer for 5 min at 95°C before separation by electrophoresis on a 
NuPAGE 4–12% Bis-Tris gradient gel (Thermo Fisher Scientific). 
The coimmunoprecipitated proteins were stained by incubation 
with colloidal Coomassie solution (0.02% Coomassie Brilliant 
Blue G-250, 5% aluminum sulfate-(14–18)-hydrate, 10% ethanol, 
and 8% orthophosphoric acid [85%]; Kang et al., 2002) at room 
temperature overnight. Bands specifically present in the CIB1-
FLAG sample but absent from the ORF75-FLAG sample were 
excised and analyzed by ion-trap mass spectrometry at the Ta-
plin Biological Mass Spectrometry Facility (Harvard Medical 
School, Boston, MA).
Gene ontology analysis
Gene ontology analysis was performed according to the PAN 
THER classification system release 20170413 (Mi et al., 2013) with 
the overrepresentation test and the Reactome version 58 (release 
20161207) against the Homo sapiens database. Bonferroni correc-
tion for multiple testing was applied. 239 mapped hits were run 
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against 21,042 database entries. The data are represented as fold 
enrichments, with P values <0.05 considered significant.
Statistical analyses
Statistical analyses were performed with Prism 5.0 (GraphPad 
Software).
Online supplemental material
Fig. S1 depicts photographs of the clinical EV manifestation of 
the studied patients. Fig. S2 depicts the results of GWL analysis 
and whole-exome filtering performed on the studied patient co-
hort and shows chromatographs obtained by Sanger sequencing 
that confirmed the mutations identified in CIB1. Fig. S3 shows 
qPCR expression data of EV-related genes after interferon treat-
ment of primary human control keratinocytes. Fig. S4 shows 
the results obtained by performing mass spectrometry after im-
munoprecipitation of CIB1 expressed in HEK293T cells as well 
as immunofluorescent microscopy and colocalization analysis 
of CIB1 and ZnT1 in primary human control keratinocytes. 
Table S1 shows the results obtained by immunophenotyping 
for the studied patients using flow cytometry. Table S2 shows 
the T cell proliferation. Table S3 shows the viral serologies. 
Table S4 shows the skin-homing T cell subpopulations. Table 
S5 shows the inbreeding coefficient. Table S6 shows the tran-
scriptomic analysis.
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